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ANG II angiotensin II
ANOVA analysis of variance
ANP atrial natriuretic peptide
AP-1 activation protein-1
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AU arbitrary units
AUC area under the concentration-time curve
Big ET-1 big endothelin-1
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bpm beats per minute
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CI confidence intervals
CI cardiac index
ĉmax maximum drug concentration
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CNP C-type natriuretic peptide
cpm counts per minute
CRF chronic renal failure
CSF cerebrospinal fluid
CTF C-terminal fragment of big endothelin
CV coefficient of variation







EC50 enzyme inhibition constant
EDHF endothelium derived hyperpolarising factor
EDTA ethylenediamine-tetraacetic acid
ERPF effective renal plasma flow
ERVR effective renal vascular resistance
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RBF renal flood flow
RIA radioimmunoassay
RMS root mean square
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SBP systolic blood pressure
SEM standard error of the mean
SHR spontaneously hypertensive rat
SI stroke index
SNP sodium nitroprusside
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swg standard width gauge
SVRI systemic vascular resistance index
TBF-p transforming growth factor-p
TFA trifluoroacetic acid
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1.1 background to the vascular endothelium
The early impression of the vascular endothelium as an inert monolayer of cells acting as a diffusion
barrier has dramatically changed recently, with the realisation that the endothelium plays a central role in
vascular homeostasis (Vane et al 1990). Indeed, it is tenable to suggest that most of the recent major
advances in therapeutic pharmacology have had their origin in the vascular endothelium, including
aspirin, nitrates and angiotensin-converting enzyme (ACE) inhibitors. Landmark work in this area
includes the discovery of prostacyclin (Moncada et al. 1976), a substance, which inhibits platelet
aggregation and causes vascular relaxation and the identification of an endothelium-derived relaxing
factor (Furchgott & Zawadzki. 1980) later identified as nitric oxide (NO) (Palmer et al. 1987). The
vascular endothelium has been further shown to release a constricting factor (Hickey et al. 1985;




Endothelin (ET) was first identified by Yanagisawa in the culture medium of porcine aortic endothelial
cells in 1988, who described it as the most potent vasoconstrictor peptide isolated to that date
(Yanagisawa et al. 1988). Later work has identified it as part of a family of three related peptides (ET-1,
ET-2 & ET-3), each of 21 amino acids, with two intra-chain disulphide bridges linking paired cysteine
residues (Figures 1.1 & 1.2, Inoue et al. 1989). ET-1 is the most potent mammalian vasoconstrictor
peptide isolated to date (Inoue et al. 1989; Yanagisawa et al. 1988) with veins 3 to 10 times more
sensitive to the effects of ET-1 than arteries, both in vitro (Cocks et al. 1989a) and in vivo (Cocks et al.
1989b). ET-1 is the major isoform produced by endothelial cells (Bloch et al. 1989) and probably the
most important in the cardiovascular system. The endothelins show remarkable structural similarities to
the sarafotoxins, a family of snake venoms (Gray & Webb 1996). They both have 21 amino-acids, 2
intra-chain disulphide bonds constraining overall structure and a conserved C-terminal sequence
necessary for biological activity and act through common receptors to elicit a multitude of effects, so
much so that isoforms of the sarafotoxins have been used to characterise ET receptors.
1.2.1 ET-1 -properties
ET-1 is the major peptide produced by human endothelial cells and is present in the greatest
concentration in the blood. When infused exogenously it causes intense vasoconstriction, which is
characteristically slow in onset, sustained and resistant to washout from isolated arteries, veins and
microcirculatory vessels of experimental animals and humans (Clarke et al. 1989). Although endogenous
levels of ET-1 are very low, in the picomolar range, ET-1 is locally active and predominately released in
an abluminal direction towards underlying smooth muscle (Wagner et al. 1992), allowing tissue
concentrations high enough to activate local receptors.
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1.2.1.1 Pressor response
The original description of ET-1 (Yanagisawa et al. 1988) described an increase in BP, following i.v.
administration of ET-1 in chemically denervated rats. In contrast with most other endogenous
vasoconstrictors this effect is sustained for > 60 minutes. This effect has also been demonstrated with
ET-2 and ET-3, with ET-3 having the least response and for the shortest duration. As well as being
demonstrated in other mammals, (Braquet et al. 1989; Pernow et al. 1996) this effect is consistent in
humans.
Furthermore this pressor effect in humans is not affected by pre-treatment with cyclosporin, calcium
antagonism with nifedipine or cyclo-oxygenase inhibition with indomethacin (Vieerhapper et al. 1992)
and occurs despite rapid clearance of ET-1 from the circulation (Anggard et al. 1989). This prolonged
effect is probably due to slsow dissociation of ET-1 from its vascular receptors.
More chronic-dosing studies have shown that prolonged infusion of ET-1 results in sustained
hypertension in rats. An effect that appears to be independent of sodium balance and mediated through
an increase in total peripheral vascular resistance (Mortensen & Fink 1990; Mortensen & Fink 1992). A
similar pressor effect is seen with big ET-1 infusion (Kashiwabara et. al 1989; Gardiner et al. 1991), and
is in contrast to a 100-fold reduced pressor potency when studied directly on blood vessels in vitro
(Kashiwabara et. al 1989). This might suggest that the action of big ET-1 is mediated via conversion to
the peptide ET-1, rather than through direct binding.
1.2.1.2 Depressor response
Although all 3 isoforms of ET show a transient hypotension, prior to the more sustained pressor
response, it is most marked with ET-3, the most ETB selective. This may be due to temporary activation
of endothelial ETH receptors, which mediate vasodilatation through production of nitric oxide and
prostacyclin. A hypothesis that is substantiated by the finding that inhibitors of NO synthase attenuate
19
this transitory hypotension (Whittle et al. 1989; Gardiner et al. 1990; Granstam et al. 1993) and by
studies showing potentiation by co-administration of ETA receptor antagonists (Cirino et al. 1994).
1.3 Endothelin genes
Regulation of endothelin synthesis is thought to take place mainly at the level of gene transcription, with
de novo production and release occurring in response to endothelial cell synthesis. Within the human
genome, the endothelins are represented by a separate gene encoding a specific precursor for the mature
isoform (Innoue et al. 1989). Three genes encoding 'ET-like' sequences in mammalian genomes (Innoue
et al. 1989) were identified soon after the original description of ET-1 and have subsequently been
shown to encode the precursors prepro ET-1, ET-2 and ET-3. In the human genome, the ET-1 gene is
found on chromosome 6, (Bloch et al,1989b) the ET-2 gene on chromosome 1 (Bloch et al. 1991) and
the ET-3 gene on chromosome 20 (Bloch et al.l989a).
ET-1 generation can be modified, either positively or negatively by extracellular factors acting through
liberation of intracellular mediators that modulate gene transcription; these include vasoactive
hormones, inflammatory mediators and physio-chemical factors such as altered shear stress and
hypoxia. Several agents enhancing ET-1 generation (Gray & Webb 1996) do so via activation of protein
kinase C (PKC). Responsiveness to PKC is mediated by binding of the proto-oncogenes Jun and Fos to
the Activator Protein-1 (AP-1) transcription regulatory element of the ET-1 promoter (Curran &
Franza. 1988; Lee et al. 1991). In the 5' flanking sequence there are binding sites for AP-1 and nuclear
factor 1 through which angiotensin II and transforming growth factor B act respectively to induce ET-1
expression. There are also binding sites for acute phase proteins, which may mediate the effects of acute
physiological stress.
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1.3.1 Processing ofendothelin precursors
The initial product of the human endothelial-1 gene is preproendothelin-1, a 212 amino-acid peptide
(Figure 1.3). After removal of the signal sequence, preproendothelin-1 undergoes the first proteolytic
step that cleaves between Lys (Berger et. al .1948) —Arg (Bergland et. al .1965) and Arg (Clouthier et. al
.1998) -Arg (Clozel 1989) to release the 38 amino acid precursor big ET-1 (Gray & Webb 1996). This
step is similar to the processing of other peptide hormones and is probably dependent on a dibasic pair
specific endopeptidase, of which furin, a proprotein convertase of the constitutive secretory pathway, is
the most likely candidate (Laporte et al. 1993).
Subsequent conversion to the mature, biologically active, peptide requires selective cleavage of the Trp
(Arai et al. 1990)-Val (Arai et al. 1993) bond in the carboxy terminal of big ET-1. This step occurs
through the action of endothelin-converting enzymes (ECE; Figure 1.5). Several ECE-like enzymes
have been identified (Opgenorth et al. 1992; Turner & Murphy. 1995), including serine proteases
(Yanagisawa et al. 1988), aspartic proteases (Takaoka et al. 1990), cathepsin D (Sawamura et al. 1990),
and soluble thiol protease (Deng et al. 1992). Although inhibitors of these enzymes can prevent
conversion of big ET-1, their contribution to ET-1 biosynthesis is not thought to be of major
physiological significance (Gray & Webb 1996).
The physiologically relevant ECE is a membrane-bound, zinc-containing metalloprotease inhibited by
the combined ECE and neutral endopeptidase inhibitor (NEP), phosphoramidon (Opgenorth et al.
1992). The activity of this ECE is not affected by thiorphan, another NEP inhibitor, or by inhibitors of
the neutral metalloprotease ACE.
1.3.2 Characteristics ofcloned endothelin-converting enzymes
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The physiologically active ECE exists in 2 different isoforms — ECE-la and ECE-lb, which have
functionally distinct roles and tissue distributions. ECE-la is an intracellular enzyme expressed in the
Golgi apparatus of cells such as the endothelial cells that synthesise ET-1, whereas responder cells, such
as vascular smooth muscle cells, express extracellular ECE-lb that can convert extracellular big ET-1 to
mature ET-1. Both ECE-1, which has a neutral pH optimum and ECE-2, which has an acidic pH
optimum (Emoto et al. 1992) are inhibited by phosphoramidon. ECE-1 is widely distributed but not
found in neural tissues, which are known to produce mature endothelins (Xu et al. 1992). ECE-2, in
contrast is abundantly expressed in neural tissues (Emoto & Yanagisawa 1995).
ECE-1 is a Type II integral membrane protein composed of 754 or 758 amino acids, with a short N-
terminal cytoplasmic tail, a hydrophobic transmembrane domain and a large extracellular domain
containing a zinc-binding motif (Gray & Webb 1996). It is highly glycosylated (Shimada et al. 1995),
with up to 10 potential glycosylation sites. There are also a number of highly conserved cysteine
residues, with studies suggesting that ECE-1 might exist as a disulphide-linked dimmer (Schmidt et al.
1994; Turner & Murphy. 1995). The 2 isoforms that do exist probably result from alternative splicing of
the ECE gene during transcription (Yorimutso et al. 1995). Despite this, no differences in the activity of
the two isoforms have yet been discovered, with both forms converting big ET-1 in preference to big
ET-2 or big ET-3.
ECE-2 is also a Type II integral membrane protein, composed of 787 amino acids, with 59% overall
sequence homology with ECE-1 (Emoto & Yanagisawa. 1995). The structure of ECE-2, is similar to
ECE-1, having a short N-terminal, a single trans-membrane domain and a large C-terminal containing a
zinc-binding motif in the catalytic domain. It is also highly glycosylated and preferentially converts big
ET-1 (Emoto & Yanagisawa. 1995). This substrate selectivity suggests that there may be yet another
ECE(s) selective for big ET-2 or big ET-3 still to be discovered.
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Although the major site for big ET-1 conversion has not been conclusively determined (Gray & Webb
1996), the current consensus is that endogenous big ET-1 is most likely to be converted during its
transit through the intracellular constitutive secretory pathways, especially within the Golgi apparatus
(Gray & Webb 1996). This conclusion is consistent with immunohistochemical staining for ET-1 in the
cytoplasm of endothelial cells and the reported ability of a low-density intracellular fraction to convert
big ET-1 to the mature peptide (Gui et al. 1993; Harrison et al. 1993). The pH in the secretory granules
of the trans-Golgi network is ~5.5, within optimum pH range for ECE-2 conversion (Emoto et al.
1995). Formation of ET-1 within secretory vesicles that can recognise transport pathways would also
provide a suitable mechanism to explain the directional release of ET-1 towards the abluminal surface
of endothelial cells (Wagner et al. 1992). ECE-1, however, works most efficiently in a neutral pFI
optimum, and therefore would not efficiently convert big ET-1 under the acidic conditions, which are
found within secretory granules, leaving the intracellular location of ECE-1 as yet undetermined.
Although endogenous big ET-1 is converted efficiently by intracellular ECE to ET-1, a proportion is
still secreted unconverted, accounting for the big ET-1 detectable in plasma (Matsumoto et al. 1994).
Although circulating big ET-1 concentrations are below the Km of ECE-1, it is likely that some big ET-
1, like exogenously administered big ET-1 (McMahon et al. 1991; Auguet et al. 1992; Haynes & Webb.
1994; Xu et al. 1994) can be converted by plasma membrane-bound ECE-1. It is possible that ECE is
localised in invaginations of the plasma membrane, called caveoli and abundant in endothelial and
smooth muscle cells (Turner & Murphy 1995; Barnes et al. 1995). This could concentrate secreted big
ET-1 for more efficient conversion by ECE-1.
23
1.3.3 Endothelin-converting enzyme inhibitors
Although phosphoramidon effectively inhibits ET-1 formation, its therapeutic potential is limited by its
low potency and lack of selectivity for ECE (Gray & Webb 1996). IC50 values for inhibition of purified
ECE-1 by phosphoramidon range from 0.35 mM to 0.8 mM, several orders of magnitude higher than
the IC50 for inhibition of NEP (Ohnaka et al. 1993; Shimada et al. 1994). To date there are no
commercially available ECE-inhibitors developed. Even if selective and potent ECE-inhibitors were
discovered, the problem of accessibility would still exist if intracellular ECE proves to be of greater
physiological importance.
1.3.4 Clearance ofendothelin
Due to efficient extraction by the splanchnic, pulmonary and renal vascular beds, the plasma half-life of
ET-1 in humans is less than 1.5 min (Gasic et al. 1992; Stewart et al. 1991). Extraction of ET-1 follows
binding to cell surface receptors, which are then internalised, allowing degradation to be carried out
within the cell (Gandhi et al. 1993). To date levels of ET-1 have been increased by both non-selective
ETa/b receptor antagonism as well as ETB receptor antagonism (Strachan et al., 1999). This would
support other evidence suggesting a clearance role for the ETB receptor (Fukuroda et al., 1994) and
indicates that the ETA receptor does not play a major role in clearance of ET-1. Low affinity ETB
binding sites that might serve this purpose have been found in arteries and veins (Gray et al. 1994;
Teerlink et al. 1994). Intracellular ET-1 degradation may be carried out by soluble proteases found in
platelets, endothelial and vascular smooth muscle cells (Deng et al. 1994; Jackman et al. 1993). NEP can
also degrade ET's, and is found in association with venous and arterial endothelial cell plasma
membranes (Lloren-Cortes et al. 1992).
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1.4 Undothetin Receptors
The ET's act on 2 receptor subtypes, ETA and ETB, classified according to their relative affinities to the
endothelin isopeptides. ET-1 has a similar binding affinity for the ETA and ETB receptors — in the
nanomolar range — and a much higher affinity for the ETA receptor than ET-3. In contrast the ETB
receptor has high and equal affinity for all three isopeptides (Sakurai et al. 1990). These respective
characteristics are closely reflected in differences in agonist potency of the isopeptide in isolated tissues,
demonstrating functionality of the binding sites (Maggi et. al, 1989)
1.4.1 ETy[ andETg receptors - general comments
After cloning the human ETA and ETB receptor have been demonstrated to exhibit ~ 60% homology
(Adachi et al. 1991; Arai et al. 1991; Elshourbagy et al. 1993). The cDNAs encoding the human ETA
and ETb receptors predict 427 and 442 amino acids, respectively. The ETA and ETB receptor genes,
located on chromosome 4 (Hosada et al. 1992) and 13,(Arai et al. 1991) respectively have similar
structural organisation suggesting that they originated from a common ancestral gene.
As with the endothelin genes, the non-transcribed 5' flanking regions of the endothelin receptor genes
contain a number of regions involved in regulation of gene transcription. Receptor transcription can be
modified by many exogenous factors, e.g., ETA receptor mRNA is up-regulated by insulin (Frank et al.
1993) and ETB receptor mRNA by angiotensin II (Kanno et al. 1993). Mechanisms such as these may
influence responsiveness of ETs in pathophysiological states. For example ETB receptor mRNA is
selectively increased in marmosets fed a high cholesterol diet (Elshourbagy et al. 1993), whereas ETA
receptor expression is reduced in atherosclerotic human arteries (Winkles et al. 1993). Prolonged
exposure to ET-1 is a major factor in reducing endothelin receptor number, due to down-regulation and
/ or feedback inhibition of receptor expression (Hirata et al. 1993).
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All the cloned endothelin receptor genes are classical heptahelical rhodopsin-like G-protein coupled
receptors that activate phospholipase C leading to hydrolysis of phosphatidyl inositol and generation of
cytosolic inositol triphosphate and membrane bound diacylglycerol (Rubanyi & Polokoff 1994). Inositol
triphosphate causes an early rise in [Ca2+], through its release from intracellular stores. A more sustained
rise of intracellular calcium occurs through opening of membrane Ca2- channels. Diacylglycerol activates
protein kinase C, increasing sensitivity of the contractile apparatus to Ca2+ and activating nuclear
signalling mechanisms causing a rise in the intracellular pH through an effect on the sodium-hydrogen
ion exchange membrane pump. ET-1 many also interact with the ATP-sensitive potassium channel, so
contributing to the rise in [Ca2+]. In addition it may activate phospholipase A,, increasing production of
arachidonic acid, and hence of prostacyclin (PGI,) and thromboxane A2 (Gray & Webb, 1996). The
transcribed region of both receptor genes encodes sites for post-translational modification that
influence the structure of the receptor and therefore linkage to intracellular messenger systems.
1.4.2 Distribution andfunction ofendothelin receptors in the cardiovascular system
ETa receptor mRNA can be detected in many tissues, with the highest expression in aorta, heart and
kidney. The ETA receptor predominates in vascular smooth muscle (Arai et al. 1990), while ETB
receptor mRNA is most abundant in endothelial cells (Hosada et al. 1990; Molenaar et al. 1993). This
would support the view that constriction of vascular smooth muscle is mediated predominantly by ETA
receptors and that this constriction is modified by release of relaxing factors from the endothelium,
partly through stimulation of ETB receptors (Figure 1.4). However, ETB receptor mRNA is also
detectable in vascular smooth muscle cells (Winkles et al. 1993) and ETB selective agonists can evoke
constriction in vitro (Shetty et al. 1993; Sumner et al. 1992) and pressor responses in vivo (Glozel et al.
1992; Williams et al. 1991), suggesting the presence of ETB receptors that mediate constriction of
vascular smooth muscle cells (Figure 1.4).
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In isolated human blood vessels, the ETA receptor subtype primarily mediates constriction in large
calibre arteries (Davenport et al. 1994), but the relative functional role of ETB receptors is greater in
small calibre arteries (Takase et al. 1995; Tschudi, & Liischer 1994). This balance of receptors may be
altered under pathophysiological conditions.
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1.5 Endothelin agonists
Synthetic ET-1, ET-2, ET-3 and sarafotoxin 6c (SX6c), an ETB agonist, are the main endothelial
receptor agonists available commercially. ETA receptors have a high affinity for ET-1 and ET-2 and a
lower affinity for ET-3, whereas the ETB receptors have equal affinity for ET-1, ET-2 and ET-3. ET-3
and especially SX6c have been used as tools to investigate the role of the ETB receptor, as ET-3 is 2000
fold selective for the ETB receptor and SX6c is 30,000 fold selective for the ETB receptor.
Although agonist studies are useful in defining target organs and receptor subtypes involved in
physiological responses to endothelins, endothelins act predominantly via autocrine and paracrine
mechanisms (Hocher et al. 1997), meaning that administration of exogenous agonist is unlikely to
reproduce physiological responses and subsequently results from such studies may be misleading.
1.5.1 Effects on Resistance Vessels
ET-1 (5 pmol/min) into the brachial artery causes a slow onset, but long-lasting dose-dependent
reduction in blood flow of ~ 40% when infused into human forearms (Clark et al 1989). ET-1 also
causes early vasodilatation (Haynes et al. 1995), with sustained vasodilatation described in one study
with ET-1 at low concentrations (0.2 pmol/min/100 ml forearm tissue) (Kiowski et al. 1990).
SX6c and ET-3, both ETB agonists, also cause constriction of forearm resistance vessels in vivo but to a
lesser degree than ET-1 (Haynes et al 1995a), thus implicating the ETB receptor in vasoconstriction.
However, ET-1, ET-3 and SX6c also caused a transient vasodilatation prior to a sustained
vasoconstriction. The transient vasodilatation is more marked with ET-3 and SX6c suggesting that this
is mediated via endothelial ETB receptors (Haynes et al. 1995b), suggesting that ETB receptors can
mediate both vasodilatation and vasoconstriction. It is postulated that the ETB receptors on the vascular
smooth muscle cells cause vasoconstriction (Williams et al. 1991, Moreland et al. 1992, Sumner et al.
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1992) while the endothelial cell receptors mediate vasodilatation (Takayanagi et al. 1991), possibly also
acting as clearance receptors for ET-1.
The exact mechanism of ET-3 and SX6c mediated vasoconstriction is unclear. It may be caused by
direct binding to the ETB receptors on the vascular smooth muscle cells resulting in vasoconstriction.
However, it may be that ETB binding causes displacement of ET-1 thus increasing stimulation at the
ETa receptor resulting in vasoconstriction. Indeed, there is animal evidence that SX6c may act through
non-endothelin dependent mechanisms, and the pressor responses may be independent of the
endothelin system (Flynn et al 1995). Local infusions of big ET-1 (50 pmol/min) produce
vasoconstriction, which can be blocked by phosphoramidon, a combined endothelin converting enzyme
(ECE) and neutral endopeptidase (NEP) inhibitor (Haynes et al 1994b). As there is limited plasma ECE
activity (Watanabe et al 1991) this would suggest that forearm resistance vessels have local ECE activity.
1.5.2. Effects on Capacitance Vessels
Constriction of dorsal hand veins is seen with ET-1 infusions of 5 pmol/min (Clark et al. 1989, Haynes
et al. 1993, 1995a), but not with local infusion of big ET-1 (50 pmol/min), suggesting no local ECE
activity in hand veins (Haynes et al. 1995b). The mechanism of action of ET-1 in hand veins is thought
to mediated via both the opening of voltage operated Ca2+ channels and the closure of ATP sensitive
K+ channels thus offering other targets for therapeutic intervention (Haynes et al. 1993b). Sarafotoxin
(SX6c) and ET-3 (ETB agonists) causes constriction of hand capacitance vessels in vivo but to a lesser
degree than ET-1 (Haynes et al. 1995a), thus implicating the ETB receptor in venoconstriction. In pre-
constricted human hand veins, as in arteries, ET-1, ET-3 and SX6c also caused a transient
vasodilatation prior to a sustained vasoconstriction. The transient vasodilatation was more marked with
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ET-3 and SX6c suggesting that it is mediated via endothelial ETB receptors (Haynes et al. 1995b), this
effect may be prostanoid dependent, as it is blocked by Aspirin.
1.5.3. Effects on Microcirculation
Intra-dermal injection of ET-1 results in vasoconstriction of the microcirculation (Wenzel et al 1994),
but intra-dermal injection of ET-3 does not, suggesting that vasoconstriction in the skin
microcirculation is an ETA mediated response. More recendy, studies have demonstrated vasodilatation,
1-2 cm from the site of injection (Wenzel et al 1998a). It appears that this is an ETA receptor mediated
effect through stimulation of polimodal nociceptor fibres leading to nitric oxide release because this
effect is blocked by BQ-123 and pre-treatment with L-NMMA, lignocaine and capsaicin. This
potentially, implicates endothelins in the process of neurogenic inflammation, suggesting ET's may
possibly have a role to play in the treatment of inflammatory conditions.
The effect of ET-1 at the ETB receptor will therefore be dependent on the balance of effects between
its actions at the endothelial and vascular smooth muscle ETB receptors. As discussed, the results of
agonist studies should be interpreted with caution as the endothelins act in a paracrine and autocrine
fashion and the administration of supra-physiological concentrations of exogenous agonists may not
mimic in vivo physiology.
1.5.4 Cardiovascular Effects ofSystemicActivation in Healthy Volunteers
The administration of ET-1 (5ng/kg/min for 15 min) to healthy volunteers results in an increase in
mean BP of 5-10 mmHg and a reduction in HR, probably reflex-mediated. This dose of ET-1 increased
plasma concentrations by 50-fold (Vierhapper et al. 1990). In more recent studies, both ET-1 (8
pmol/kg/min for 10 min) and big ET (8 pmol/kg/min) infusions, sufficient to cause increases in
plasma ET-1 of 30 and 2.4 fold respectively, caused similar increases in BP and a reduction in HR
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persisting for 30 and 90 min respectively after stopping the infusion. These doses of ET-1 and big ET-1
also reduce coronary sinus blood flow, by ~25%, and increase coronary vascular resistance by ~50%
and 100% respectively (Pernow et al. 1996). Furthermore doses of ET-1 insufficient to cause systemic
or pulmonary pressor effects (0.75 pmol/kg/min) can cause diastolic dysfunction and are negatively
inotropic (Kiely et al. 1997).
1.6 Endothelin receptor antagonists
Several endothelin receptor antagonists have been developed of varying selectivity. Some are peptides
and therefore orally inactive, such as BQ-123, which has 2000-fold selectivity for the ETA receptor
(Ihara et al. 1992) and BQ-788, which demonstrates 200-fold selectivity for the ETB receptor (Ishikawa
et al. 1994) and TAK-044, a mixed ETA/B antagonist (Kikuchi et al. 1994). Other, orally active
endothelin receptor antagonists include bosentan, a mixed ETA/B receptor antagonist.
1.6.1 Effects on Resistance Vessels
Local infusion of BQ-123 (Flaynes et al. 1994, Berrazueta et al. 1997, Verhaar et al. 1998) and TAK-044
(Haynes et al. 1996) causes vasodilatation in forearm arteries of healthy volunteers. BQ-123 causes
greater vasodilatation than TAK-044, suggesting vasoconstriction to ET-1 is primarily mediated through
ETa receptors located on vascular smooth muscle cells. Inhibition of the ETB receptors results in a net
effect of vasoconstriction. The role of the ETB receptor has been further clarified by studies with the
ETb receptor selective antagonist, BQ-788 (Ishikawa et al 1994). BQ-788 causes vasoconstriction in the
forearm vessels of healthy volunteers persisting despite ETa antagonism (Verhaar et al 1998),
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reinforcing the hypothesis that ET-1 causes dilatation at the endothelial ETB receptor and
vasoconstriction at the vascular smooth muscle ETB receptor.
1.6.2. Effects on Microcirculation
In the skin microcirculation of healthy volunteers, intra-dermal injection of a mixed ETA/B antagonist
causes vasodilatation, similar to that seen with selective ETA antagonism suggesting vasoconstriction to
endothelin is solely ETA receptor mediated (Wenzel et al. 1994). In patients with coronary artery
disease, however, there is increased vasodilatation with mixed ETA/B antagonism versus ETA
antagonism, suggesting ETB receptor mediated vasoconstriction in these patients (Wenzel et al. 1996).
In addition, intravenous administration of bosentan reverses the vasoconstrictor effect of ET-1
measured in the skin microcirculation (Weber et al. 1996). In a more recent study, pre-treatment with
intra-dermal ETA receptor antagonist prevents ET-1 induced vasoconstriction and vasodilatation in the
surrounding area. There is no additional effect with mixed ETA/B antagonist suggesting the flare
reaction is ETA receptor mediated (Wenzel et al. 1998). Thus, in the skin microcirculation ETA receptors
appear to be involved in endothelin-mediated vasoconstriction and to mediate distal vasodilatation.
1.6.2 Cardiovascular Effects ofSystemicActivation in Healthy Volunteers
The results of systemic studies with endothelin receptor antagonists have, in general confirmed
predictions made from local vascular studies.
1.6.2.1 Non-selective Inhibition
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TAK-044, a mixed ETA/B antagonist reduces systolic BP, diastolic BP and SVR by 4%, 18% and 26%
respectively and increases MR and cardiac index and plasma ET concentrations. These results suggest
an effect predominantly in resistance vessels (Haynes et al. 1996). The increase in plasma ET is probably
due to displacement of bound ET-1 and reduced ET-1 clearance, as there is no associated increase in
big ET-1 or its C-terminal fragment (Plumpton et al. 1996). Similar results are found in healthy
volunteers given oral and intra-venous bosentan (Weber et al. 1996).
1.6.2.2 Selective inhibition
To date there have been no studies examining the effects of either selective ETA receptor antagonism or
ETb receptor antagonism. The results of the forearm studies mentioned earlier may suggest a
haemodynamic benefit (either in health or in disease states, such as CHF) of selective ETA receptor
antagonism compared with non-selective receptor antagonism — a hypothesis that underlay the design
of Study 5. Prior to this it was necessary to confirm, by systemic administration, studies in the forearm
resistance vessels showing vasodilatation to ETA receptor antagonism - a hypothesis that underlay the
design of Study 2.
Earlier results in the forearm would also suggest that systemic ETg receptor antagonism would result in
a rise in SVR and MAP a hypothesis that underlay the design of Study 3.
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1.7 Endothelin and cardiovascularpathology
1.7.1 Hypertension
In patients with essential hypertension there is an increased venoconstrictor response to local ET-1 (5
pmol/min) and sympathetically mediated venoconstriction of capacitance vessels is potentiated by ET-1
(Haynes et al. 1994). Vasodilatation in patients with essential hypertension following intra-arterial
administration of BQ-123 is no different to that seen in normal healthy volunteers, suggesting no major
dysfunction of endothelium dependent vasodilatation (Ferro et al. 1996b).
Results of systemic studies performed with hypertensive patients have recently been reported. Bosentan
(4 weeks) causes significant lowering of BP without reflex neurohormonal stimulation of the
sympathetic nervous system or renin-angiotensin system. Bosentan caused a similar reduction in BP to
that seen with 20 mg of the ACE inhibitor enalapril (Krum et al 1998).
1.7.2 Coronary artery disease (CAD)
There have been few studies performed specifically in patients with coronary artery disease. In healthy
volunteers, intra-dermal injection of mixed ETA/B receptor antagonist causes a similar vasodilatation to
selective ETA receptor antagonism in the skin microcirculation. However, in patients with CAD, mixed
inhibition causes a greater vasodilatation (Wenzel et al. 1996) suggesting that the ETB receptor may have
increased functional significance in patients with CAD.
When bosantan is given to patients with angiographically documented coronary artery disease a decrease
in systolic BP and a small increase in HR is seen. In addition, there is a maximal increase in coronary
artery diameter, with no further increase was noted after treatment with glycerol trinitrate suggesting
basal coronary artery vasoconstrictor tone, in vivo is mediated by endogenous ET (Wenzel et al. 1998b).
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1.7.3 Congestive cardiacfailure
The syndrome of CHF, which is most commonly caused by ischaemic heart disease, is characterised by
diminished cardiac output (CO) and reserve. The reduction in CO is associated with reflex activation of
neurohumoral responses involving the renin-angiotensin system (RAS) and the sympathetic nervous
system (SNS), which promote vasoconstriction, tachycardia, sodium and water retention and expansion
of the extracellular fluid compartment (Levine et al 1982). Although these responses act in the short
term to maintain CO, BP and the blood flow to vital organs, they also increase cardiac pressures and
workload. In the longer term neuroendocrine activation contributes to progressive 'remodelling' of the
left ventricle and an associated decline in cardiac function. To date, only drugs that block the RAS
(Cohn et al 1986, CONSENSUS 1987, SOLVD 1991) and those that modify the harmful actions of the
SNS (CIBIS I 1994, Packer et al 1996) have been conclusively demonstrated to improve the survival of
CHF patients, supporting the central importance of neuroendocrine activation in the poor outcomes
associated with CHF. Indeed, recent studies continue to confirm this hypothesis (RALES 1998, CIBIS
II 1999).
The function of the endothelium is disturbed in CHF leading to reduced responsiveness to
endothelium-dependent vasodilators in both the peripheral (Kubo et al 1991; Katz et al 1992) and
coronary vessels (Holdright et al 1994). The increase in vasomotor tone seen in CHF represents the net
effect of the interaction of locally produced factors with systemically activated vasoconstrictor reflexes,
especially the SNS and RAS. Circulating concentrations of big ET-1, the precursor of ET-1, and ET-1
itself are significantly increased in CFIF and relate strongly to morbidity and mortality (McMurray et al
1992, Packer et al 1996). These changes may contribute to the characteristic increase in SVR and left
ventricular afterload in CHF. Drugs infused locally to block ET-1 production or actions cause
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significant peripheral vasodilatation in CHF patients even in the presence of ACE inhibition (Love et al
1996), suggesting that local ET-1 release makes a significant contribution to the increased SVR. Local
brachial artery infusion of ET-1 (5 pmol/min for 60 min) causes less vasoconstriction compared with
matched controls in resistance (Love et al. 1996b) and capacitance vessels (Love et al. 1996c). In turn
local brachial artery infusion of BQ-123 causes vasodilatation. Although there is increased
vasoconstriction to the ETB receptor agonist, S6Xc (5 pmol/min for 60 min), in CHF patients when
compared with matched controls, BQ-788 also causes vasoconstriction, suggesting the net effect of
stimulation of the ETB receptor is vasodilatation.
In animal models of CHF long-term survival is increased after both selective ETA receptor blockade
(Sakai et al 1996) and mixed ETA/B receptor blockade (Mulder et al. 1997). The vasodilatation seen with
ETa antagonism may, in part, be mediated by NO acting via the endothelial ETB receptor (Verhaar et al.
1998; Figure 2). This may have added importance because NO has anti-proliferative, anti-mitogenic and
anti-platelet actions (Moncada et al. 1991) that may be beneficial in CFIF and related conditions. If these
findings with ETA and ETB antagonists in the forearm circulation were extended to the systemic
circulation, one might conclude that selective ETA receptor antagonists would offer distinct
haemodynamic, and probably additional clinically relevant advantages (Haynes & Webb, 1998), over
non-selective ETA/B receptor antagonists for CFIF patients.
Kiowski and colleagues first investigated the systemic haemodynamic effects of bosentan, a 'mixed' ETA/B
antagonist (though actually 100-fold more active against ETA than ETB receptors), in patients with CFIF
withdrawn from ACE inhibitor treatment (Kiowski et al. 1995). Bosentan decreased SVR and MAP,
while substantially reducing pulmonary vascular resistance and increasing cardiac index, without a
significant effect on FIR and importantly no increase in plasma angiotensin II or noradrenaline (Kiowski
et al. 1995). These findings were confirmed in patients with coronary artery disease (Wenzel et al 1998).
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More recently bosentan has been shown to cause substantial haemodynamic benefits in CHF patients,
already treated with conventional therapy including ACE inhibitor therapy, that were sustained for 14
days (Sutsch et al. 1998). It was, therefore, on this basis that we designed Study 5 to investigate the
effects of short-term infusions of BQ-123 compared with the combination of BQ-123 and BQ-788.
Our initial working hypothesis was that selective ETA receptor antagonism would have additional
haemodynamic benefit over non-selective ETA/B receptor antagonism.
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1.8 Conclusions
Endothelin antagonists have proved extremely useful in extending our understanding of cardiovascular
physiology and for providing new insights into the pathophysiology of cardiovascular disease. A broad
body of experimental and clinical evidence now exists to support the clinical development of drugs that
block the production or actions of endothelin for use in cardiovascular medicine. There is particularly
good evidence to support their development in conditions associated with chronic vasoconstriction,
such as hypertension and heart failure. It is still not clear whether mixed ETA and ETB receptor
antagonists have therapeutic advantages over selective ETA receptor antagonists, as both receptors can
contribute to ET-1 induced vasoconstriction in humans. Currently, combined ETA and ETB receptor
antagonists appear to have the widest potential for clinical application and are currently under
investigation. These drugs represent a novel therapeutic approach to a fundamental and newly




Figure 1.1 Endothelin & isoforms
Endothelin-1 is a 21-amino acid peptide with 2 intra-chain disulfide bridges linking paired cysteine
residues.
Figure 1.2 Endothelin synthetic pathway
The gene encoding ET-1 on chromosome 6 contains 5 exons and 4 intervening intron sequences. Once
translated, an amino terminal sequence (amino acids 1-17) is cleaved on secretion of the prepro peptide
from the nucleus. Big ET-1 is formed through proteolysis of pro ET-1 by dibasic pair endopeptidase
enzymes and then mature ET-1 is formed through cleavage of big ET-1 at Try21-Val22 by a specific
endothelin converting enzyme.
Figure 1.3 Big endothelin-1 and C-terminal fragment
Big ET-1 is cleaved at Try21-Val22 by a specific endothelin converting enzyme to form ET-1 and the C-
terminal fragment of big ET-1. In certain conditions associated with raised plasma concentrations of
ET-1, measuring plasma concentrations of big ET-1 and/or C-terminal fragment may help distinguish
increased production of ET-1 or decreased clearance of ET-1 as the cause of the raised ET-1
concentrations.
Figure 1.4 Vascular effects of endothelin and its receptors
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Endothelin produced by endothelial cells acts on two receptors: ETa and ETg. Both these receptors are
located on smooth muscle cells and mediate smooth muscle contraction by increasing intracellular
calcium. The ETg receptor is also found on endothelial cells and mediates smooth muscle vasodilatation
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2.71 Calculation ofaugmentation index
2.72 Typicalplethysmography set-up
2.73 Typicalplethysmograph pressure waveform
2.1 Venous Occlusion Plethysmography
Human studies of blood vessels in vivo using systemic doses of drug can cause effects on other organs
and stimulate neurohumoral reflexes by changes in systemic haemodynamics. This makes the direct
vascular effects of study drugs difficult to interpret. To avoid these confounding influences, locally
active doses of drugs can be infused into single regional vascular beds enabling the study of vascular
pharmacology in resistance and capacitance vessels in humans (Aellig 1981; Whelan 1967).
2.1.1 Principle
Venous occlusion plethysmography has been used to measure limb blood flow for over 80 years
(Hewlett & Van Zwaluwenburg 1909). Although air and water plethysmographs have been replaced by
externally applied galhum/indium-in-Silastic and mercury-in-Silastic strain gauge devices (Haynes &
Webb 1994; Newby et. al. 1997) the underlying principle remains the same. A proximal limb cuff is
inflated rapidly to greater than venous pressure but lower than arterial pressure, halting venous return
but not affecting arterial inflow. The increase in limb volume with time thus gives a measure of arterial
blood flow. In strain gauge plethysmography, changes in limb circumference, and hence limb volume,
are detected as a change in electrical resistance of the gauge. Because limb circumference and not
volume is measured by the strain gauge technique, a measure of blood flow per unit volume of tissue
(ml.min1.100 ml1 tissue) is obtained. Limb volume must be measured separately in order to obtain an
absolute measure of blood flow, though for many studies this is not necessary. The mathematical
principles underlying this technique have been reviewed (Ensink & Hellige 1981). Although early studies
often involved the lower limb, the studies in this thesis use only the forearm vascular bed.
47
2.1.2 Technique
Subjects are made to feel relaxed resting supine in a comfortable, quiet, draught-free environment
maintained at a constant temperature between 22 and 26°C to minimise variability in blood flow and BP
and therefore maximise reproducibility of results. The arms are maintained resting comfortably, above
the level of the central venous pressure and with venous emptying unimpeded, so that venous pressure
cannot rise sufficiently to affect arterial inflow during measurements (figure 2.3). The upper arm cuff is
inflated to 40 mm Hg for 10 seconds and then deflated for 5 seconds, a manoeuvre, which does not
affect arterial inflow or pressure (Wilkins & Bradley 1946) and generally provides analysable linear
tracings (Figure 2.4) (Greenfield et. al. 1963). At high flow rates, a shorter inflation period and a longer
deflation period are needed to ensure adequate venous emptying. Recordings of forearm blood flow
(FBF) are made repeatedly over 3-minute periods. Voltage output from a dual-channel Vasculab SPG
16 strain gauge plethysmograph (Medasonics Inc) is transferred to a Macintosh personal computer
(Performa 475, Apple Computer Inc, Cupertino, CA) using a MacLab analogue digital converter and
Chart software (v. 3.2.8; both from AD Instruments, Casde Hill, NSW, Australia). Calibration is
achieved using the internal standard of the Vasculab plethysmography units.
During measurements, hand blood flow is excluded by wrist cuffs inflated to 220 mm Hg. As flow only
stabilises after 60 seconds of cuff inflation (Kerslake 1949) cuffs must be inflated for 60 seconds longer
than the period of measurement. Hand ischaemia limits the time of any one period of measurement to
~10 minutes. Venous occlusion plethysmography has been shown to be a reliable (Ensink 1981) and
reproducible technique in individual subjects (Roberts 1986)
Compared with muscle blood flow, skin blood flow varies more markedly with temperature and
emotion, (Abramson 1940) has a different physiology and exhibits different responses to drugs.
Compared with the forearm, the hand is primarily made up of skin. In addition, the tissues of the hand
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cannot stretch in the same way as those of the forearm, and inclusion of the hand during FBF
measurements can result in non-linear and immeasurable flows. Therefore, hand blood flow is excluded
during measurements of FBF. Even with hand exclusion, it should be recognised that blood flow to
skin contributes to total FBF (Cooper et. al. 1955), accounting for ~25% of flow <6 ml.lOOml.'min"1
and as much as 50% of higher flows.
2.1.3 Arterial administration
Barcroft and colleagues (Allen et. al. 1946) first described arterial cannulation to assess responses of
skeletal muscle to local drug administration in 1946. They infused adrenaline into the femoral artery
(although now most workers use the brachial artery route), and noted that this technique could be used
to examine the direct effects of a drug on the resistance vessels without eliciting effects mediated
through actions on other organs or by stimulation of neurohumoral reflexes. These unwanted effects
are avoided by giving doses that do not have systemic actions, which is feasible because the blood flow
to the forearm at rest is low (~50 ml.min4) compared with the cardiac output (5000 ml.min"1). Hence,
doses 100- to 1000-fold lower than those active systemically are effective within the upper limb
circulation. Assuming that drugs are used for short periods, and / or actions are short-lived, their effects
are restricted to the infused limb. The opposite arm can then act as a contemporaneous control for the
experimental arm receiving drug, taking account of any minute-to-minute changes in blood flow that
affect both arms, such as due to emotion or minor changes in basal state (Benjamin et. al. 1989). In
general, although the forearm is obviously only one of several resistance circuits, effects in the
circulation to forearm muscle are commonly predictive of those found in other major systemic
resistance beds, such as the mesentery and the kidney (Webb 1995).
Drugs are infused via a Welmed PI 000 syringe pump (Welmed Clinical Care Systems), with the total
rate of infusion maintained constant throughout at 1 ml.min"1, through a cannula sited in the brachial
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artery at the elbow under local anaesthesia with lignocaine (Astra Pharmaceuticals Ltd, Herts, UK). Very
fine steel needles (27 SWG: Cooper's Needle Works, Birmingham, UK) mounted on a 16-gauge
epidural cannula (Portex Ltd) are used. They are regularly checked for 'flashback' of blood at intervals
during the studies to ensure correct placement. These needles have been found to be safe and
atraumatic, consistent with the safety of long-term siting of larger brachial and radial artery cannulae in
clinical practice (Moran et. al. 1988; Gardner et. al. 1974). The technique is also extremely well tolerated
allowing studies to be repeated at 1- to 2- week intervals up to 6 times in the same subjects (Haynes &
Webb 1994). Some researchers use cannulae of a size sufficient to allow direct measurement of arterial
blood pressure. However, these are less well tolerated, and therefore difficult to justify ethically. Except
in unusual circumstances, the combination of intermittent non-invasive measurement of blood pressure,
either at the brachial or digital artery, with measurement of blood flow in the control arm is sufficient
for safety purposes and to exclude a systemic drug effect.
In these local infusion studies, particularly with potent vasoconstrictors, data from animal pharmacology
studies are of great importance. Although critical closure is theoretically possible in resistance vessels
maintaining constant transmural pressure in the face of an increasing tension secondary to
administration of a vasoconstrictor agent, this has not been observed in practice even with major
reductions in local blood flow caused by ANG II (Benjamin et. al. 1989) and ET-1 (Haynes et. al. 1991).
It should be noted that, where pharmacological considerations have been taken into account,
vasoconstrictors have proved remarkably safe in the forearm, avoiding the potential hazards that might




Separate issues relate to the infusate. It is important to use the appropriate vehicle as the time control
for the active drug, particularly if the pH of the infusate has to be non-physiological in order to dissolve
the drug or if one component of the vehicle might have vasoactive properties. To avoid these problems,
physiological (0.9%) saline is used to dissolve agents for arterial infusion. It is also critical to avoid the
use of hyperosmolar solutions for infusion as these can cause substantial vasodilatation (Overbeck et. al.
1970). Where possible, infusate flow of >lml.min 1 and changing infusate flow rate should be avoided,
because this can make a measurable contribution to total blood flow, especially during the infusion of
vasoconstrictors. Clearly, some drugs cannot be given, even at locally active doses, in humans because
of the potential for toxicity. However, if particular concerns exist about local vascular inflammatory
effects of the infusate from intravenous studies in animals or humans, specific testing in the rabbit ear
artery can be helpful.
2.1.5 Analysis ofResponses
In a fasted subject resting comfortably in the supine position in a quiet, warm, temperature-controlled
environment, BP and FBF remain stable for several hours (Webb 1995). Although there may be small
fluctuations in blood flow associated with changing levels of alertness, these affect both arms
simultaneously, so blood flow in the control arm can serve as a contemporaneous control for drug
effects in the infused arm. In general, the effects of external stimuli on drug responses, and the inter-
subject variability in drug effects, are minimised by describing the drug effect as the percentage change
from baseline of blood flow in the infused arm as a ratio of the same percentage change in the control
arm. This method uses all the information obtained from flow measurements, and serves to minimise
the effects of variations in blood flow caused by minor external factors (Benjamin et. al. 1989).
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The validity of this method for handling the data is dependent on arterial pressure remaining stable
during the experiment, in which case changes in blood flow provide a reliable measure of drug effect on
the contractile state of the smooth muscle. Some workers use flows and pressures to calculate changes
in vascular 'resistance', although with a non-newtonian fluid, a distensible vascular system and pulsatile
flow, this derived parameter offers no particular advantage (Webb 1995).
If significant changes in arterial pressure do occur, the results must be interpreted with considerable
caution because the contractile state of the smooth muscle is not independent of distending pressure,
depending on the balance between passive stretch caused by the increased pressure and the evoked
contraction of the circular smooth muscle (autoregulation). There is much variability between subjects
in the response of the forearm vascular bed to changes in arterial pressure (Robinson 1990) and no
simple way of distinguishing the autoregulatory response from the direct effect of a drug.
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2.2 Blood Pressure Measurements
A semi-automated noninvasive oscillometric sphygmomanometer (Takeda UA 751, Takeda Medical Inc,
Tokyo, Japan) was used to make duplicate measurements of BP in the non-infused arm, which were
then averaged. This system has been well validated against intra-arterial BP measurements, ordinary
auscultation and semi-automatic devices using the microphone detection of Korotkoff sounds for the




Impedance cardiography (bioimpedance) is a simple, accurate and non-invasive method for measuring
cardiac output (CO) and function. A constant sinusoidal current is applied between electrodes placed on
the neck and lower chest and changes in the current bioimpedance related to cardiac events and blood
flow. The major change involved is reduction in impedance (Z) during left ventricular ejection. The first
derivative of this impedance cardiogram (dZ/dt) includes inflections timed with cardiac events such as
aortic valve opening and closure and peak systolic aortic flow and the maximum change in dZ/dt
(dZ/dt[max]) is related to peak aortic flow (Mohapatra 1981). By measuring the intervals between
impedance reflections and those on the ECG it is possible to derive systolic time intervals (STIs) such
as the pre-ejection period (PEP) and ventricular ejection time (VET). These and the ratio PEP / VET,
relate to left ventricular performance and have been used non-invasive assessment of drug effects
(Caplan et. al. 1987; Weissler 1977).
The impedance cardiogram can be also been used to determine stroke volume. Using a model in which
the chest is considered to consist of two parallel conductors (blood and thoracic tissues), and making
several approximate assumptions about the relationship between the impedance cardiogram and aortic
blood flow, Kubicek et al (Kubicek et al 1976), devised a plethysmographic formula for estimating
stroke volume from systolic thoracic impedance change. While the formula produced acceptable
estimates of stroke volume and CO at rest and with exercise in healthy volunteers, it was sometimes
inaccurate, especially in patients with cardiovascular disease (Donovan et. al. 1986).
More recently Sramek and Bernstein have described an empirical modification to Kubicek's original
formula (Bernstein 1986) combined with a computer algorithm to produce a simple and cheap method
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for measuring stroke volume. Several studies have shown that the new method is more accurate in the
clinical setting than Kubicek's (Appel et. al. 1986; Northridge et. al. 1990; Spinale et. al. 1988; Thomas
1992).
2.3.2 Technique
Impedance measurements were made using a Non-invasive Computerised Cardiac Output Monitor
(NCCOM) 3, series 6 (Biomed Medical Manufacturing, Irving, California) impedance cardiograph. A
constant sinusoidal alternating current (2.5 mA RMS, 70 kHz) was applied between electrode pairs
placed on the lateral aspects of the neck and lower chest and the voltage detected by two inner-sensing
electrode pairs placed 5 cm from the corresponding current injecting electrodes and parallel to the
current path. Self-adhesive Ag/AgCl electrodes (Red Dot 3M, Minneapolis USA) were used. This
voltage was relayed to an amplifier within the apparatus. An impedance (Z) signal was produced using
Ohms law and differentiated to give the dZ/dt signal. A microprocessor incorporated in the apparatus
uses algorithms to produce on-line measurements of basal impedance (Z0), peak rate of change of
impedance (dZ/dt[max]), and VET. Stroke volume and CO are calculated on-line by the
microprocessor using the Sramek-Bernstein formula:
Stroke volume = L3.dZ/dt[max].VET / Z0.
Were L is the thoracic length, estimated from the patient's height and weight using a normogram
(Bernstein 1986).
Using this method, both absolute CO and changes in CO measured by bioimpedance agree closely with





In the majority of situations non-invasive cardiovascular monitoring provides enough information
about haemodynamic change for further invasive monitoring to be regarded as an unnecessary risk. In
the assessment of pharmaceutical intervention on the pulmonary circulation, or on left atrial filling
pressures, there is little in the way of alternative. Of the techniques available for right heart
catheterisation, balloon-flotation catheters are the simplest and most widely used. Right-heart
catheterisation allows measurement, albeit indirectly, of left atrial pressures as well as pulmonary artery
and right ventricular pressures.
Swan-Ganz Catheterisation involves insertion of a flexible, balloon-tipped catheter into right side of the
circulation and pulmonary artery for haemodynamic monitoring. Intravascular pressures are measured
by a fluid-filled catheter, attached to a pressure transducer. The pressure wave is transmitted from the
catheter tip to the transducer by the fluid column within the transducer. The pressure wave than distorts
the wire within the transducer. This energy is then converted to an electrical signal, which is
proportional to the pressure applied. The signal is then amplified and recorded as an analogue signal
(Grossman & Bairn 1991).
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2.4.2 Technique
The pressure transducer must be first calibrated against a known pressure or 'zeroed' prior to
commencing the procedure. To 'zero' the transducer, it is placed at the level of the heart with the
transducer. The skin and subcutaneous tissue is then infiltrated with lignocaine (1%) via a small gauge
needle. A large gauge needle (16- or 18-gauge) is attached to the syringe and placed into the vessel
following the course of the "finder needle." When blood is easily aspirated, the syringe is disconnected
from the needle and a flexible guide-wire threaded through the needle into the vein. Once the guide-
wire passes into the vessel, the needle is removed and a dilator advanced over the guide-wire and
through the skin, facilitating passage of the venous introducer. The introducer is flushed with
heparinised saline prior to insertion, put together as a unit (dilator within introducer) and slid over the
guidewire into the vein. The guidewire and dilator are removed, leaving only the venous introducer
sheath within the patient. The introducer is then secured to the patient's skin with sutures.
Prior to catheter insertion, the balloon tip is checked under sterile water for leaks and the catheter
flushed. The catheter is then connected to the monitoring lines and flushed again via the pressure
tubing ensuring that the catheter is bubble-free and that a column of uninterrupted fluid exists from the
tubing through the tip of the catheter. The catheter is then guided via the introducer, under direct
fluoroscopic guidance, via the right femoral vein up the inferior vena cava, through the right atrium
(RA), right ventricle (RV), pulmonary artery (PA), and into the wedge position. The catheter position is
ascertained by a combination of pressure waveforms and fluoroscopy.
When an indirect measurement of left atrial filling pressure is required the catheter is "wedged", by
inflating the balloon with 5cm of air and thereby briefly occluding a small pulmonary artery branch.
Direct pressure measurements are obtained in the pulmonary artery. The catheter can also be used to
measure CO, SVR and mixed venous oxygen saturation.
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2.4.3 Calculation ofcardiac output
The Swan-Ganz catheter is designed with a proximal and distal thermistor and calculates cardiac output
based on the thermodilution procedure. This requires the proximal thermistor coil to deliver a set
amount of energy automatically every 30 seconds, which is transmitted into a rise in temperature and
measured by the distal thermistor. The CO is then calculated as being inversely proportional to the area
under the temperature-time curve, using the following formula:
Q = 60(VjSjQCF^g - Tj) / [SBCjo"ATB(t)dt]
CO is then adjusted for body surface area as follows:
CI = CO / BSA (L / min / m2)
Where CI = cardiac index; CO = cardiac output, Lmin"1; BSA = body surface area, m2.
2.4.4 Calculation ofsystemic vascular resistance
SVR is a derived value, which can be useful in describing the interaction between the systemic and
pulmonary circulation. Pousuille's law states that the ratio of pressure gradient to flow is a function of
dimension and viscosity flowing through the tube. The ratio of mean pressure gradient to mean flow is,
thus, a measure of the extent to which a system opposes or resists flow. In the context of the circulatory
system, this ratio is called vascular resistance (R) and is analogous to the definition of electrical
resistance in Ohm's Law:
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R = mean pressure gradient / mean flow
Systemic vascular resistance is further defined as:
SVR = {(MAP - CVP) x 80} / CO (dynes-sec / cm5)
Where MAP = mean arterial pressure, mmHg; CVP = central venous pressure, mmHg; CO = cardiac
output, Lmin"1
This is further adjusted for body size and expressed as systemic vascular resistance index, as follows:
SVRI — SVR / BSA (dynes-sec-m2) / cm3
It should be noted that using the above calculations, only the opposition to mean flow is calculated,
which largely neglects the pulsatile components of cardiac loading.
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2.5 Plasma Assays
All venous blood samples were collected into chilled tubes, centrifuged at 1500 g for 20 minutes at 4°C
and stored at -80°C until assay. All assays were done in single batches.
2.5.1 Measurement ofPlasma Aldosterone
Venous blood samples for plasma aldosterone concentrations were collected into lithium heparin tubes
and plasma aldosterone was measured using a solid-phase (coated tube) radioimmunoassay from
unextracted serum using a commercially available kit (Coat-a-Count; Diagnostic Products Corporation,
Los Angeles, CA). The intra-assay CV is <8.3%.
2.5.2 Measurement ofPlasmaAngiotensin II
Venous blood samples were taken into EDTA/o-phenanthroline to inhibit converting enzyme and
angiotensinase enzymes (Diisterdieck & McElwee. 1971).
The method for radioimmunoassay of ANG II is described in described in detail in Morton, 1985
(Morton & Webb. 1985). In brief, samples were extracted by passage through Sep-pak CI 8 cartridges
(Waters Associates, Milford, MA). The cartridges were pre-treated with methanol (5 ml) and then water
(5 ml). Plasma (5 ml) was then passed through the cartridge under gentle vacuum. After washing with
water (5 ml), ANG II was then eluted from the column with aqueos 20% methanol (2 ml). The extracts
were dried and re-dissolved in Tris buffer (50 mmolT1; pLI 7.5) for assay. The recovery from plasma of
added ANG II was 95%. The intra-assay CV is 10%.
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2.5.3 Radioimmunoassay for Endothelial, Big Endothelin-1 and C- of Big Endothelin-1
Samplepreparation
After being thawed, 5 ml plasma samples were acidified by adding 1 ml hydrochloric acid 2 M, and
clarified by centrifuging for 15 min at 2000 g at 4°C. The resulting supernatants were applied to
activated supernatants 500 mg Spe-ed CI 8 (14% carbon coverage) disposable mini-columns using a
vacuum manifold (Applied separations, Laboratory Impex Ltd, Middx.). Unbound materials were
washed from the mini-columns with a vacuum manifold with a 5 ml 0.1% TFA and discarded.
Immunoreactive CTF was eluted with a subsequent 2 ml of 80% methanol, 0.1% TFA and
immunoractive endothelin and big ET-1 were separately eluted with a subsequent 2 ml of 80&
methanol, 0.1% TFA. Eluates were evaporated to dryness in polypropylene tubes using a Savant sample
concentrator (Life Sciences International (UK) Ltd. Basingstoke, Flants).
Radioimmunoassay
Plasma IR endothelin, big ET-1 and CTF were determined by radioimmunoassay using rabbit antisera
raised against the C-termini of endothelin (ET-1 (Angaard & G. Rae 1991) and big ET-1 (Bakris et. al.
1993). Plasma extracts were reconstituted in assay buffer (50 mM sodium phosphate, 0.25% bovine
serum albumin (BSA), 0.01% Tween 20, 0.05% sodium azide, pPI7.4) and incubated in duplicate with
diluted antisera overnight at 4°C. Following a further overnight incubation with ~10,000 c.p.m./tube
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tracer ( " -ET-1 or -big ET-1, Amersham International pic, Amersham, Bucks), bound counts were
separated using Amerlex-M reagent (Amersham International pic) and radioactivity determined in a
gamma counter (Canberra Packard, Pangbourne, Berks). Immunoreactivity was calculated by reference
to standard curves (0.5 - 1000 fmol/tube) of authentic ET-1 (Peptide institute, Scientific Marketing
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Associates. Barnet, Herts or Novabiochem Ltd, Nottingham), or big ET-1 (Peninsula Laboratories Ltd,
St Helens Lanes). For both assays, ED50 values were 20-25 fmol/tube, inter- and intra-assay coefficients
of variation were <13% in the range 6-30 fmol/tube and the sensitivities of detection (defined as 2 s.d.
above zero standard) were <1.25 fmol/tube. The recoveries of ET-1, big ET-1 and CTF were 57.5%,
39.8% and 76.6%, respectively (n=4).
The mature endothelin RIA cross-reacted 100% with ET-1, ET-2 and ET-3 as expected as the
immunogen contained the 7 C-terminal residues of ET-1 common to all 3 mature ET isoforms. Cross-
reactivity with ET-1, big ET-1, big ET-1, big ET-2 and big ET-3 were <0.02%. The big ET-1 RIA
showed <0.007% cross-reactivity with the mature endothelins, big ET-2 and big ET-3, and cross-
reacted 143% with big ET-1, thus allowing the quantification of CTF following fractionation. No cross-
reactivity was detected (<0.005%) at the highest concentrations tested with unrelated vasoactive
peptides such as ANG II, ANP and a-calcitonin gene-related peptide.
2.5.4 BQ-123 Assay
BQ-123 levels in plasma were measured by high performance liquid chromatography (HPLC) with
fluorescent detection. One volume of plasma had lOul of TAK-044 (Takeda, Takeda Medical Inc)
added as internal standard, was precipitated with 4 volumes of ethanol, centrifuged at 4 °C for 15 min at
lOOOOg, and the resulting supernatant injected into the HPLC column. The HPLC system consisted of a
Waters 510 FIPLC pump, WISP intelligent sample processor and Spherisorb S5 ODS column (Waters
Ltd, Watford, Herts. UK) with detection by LS-5 fluorometric detector (Perkin-Elmer Ltd,
Beaconsfield, Bucks. UK) with excitation and emission wavelengths of 284nm and 348nm respectively.
The mobile phase consisted of 60:40 Acetonitrile: de-ionised water with tri-fluoroacetic acid at a
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concentration of 0.1%. Recovery of BQ-123 from plasma was found to be 107% and the intra- and
inter-assay variations were 5.8% and 9.6% respectively.
2.5.5 Radioimmunoassay ojAtrialNatriuretic Peptide
Blood samples (10 ml) were collected in chilled tubes containing EDTA as anticoagulant and enough
Trasylol to give a final concentration of 50 Kallikrein inhibitor units.ml1 (Richards et. al. 1987).
The method for radioimmunoassay of ANP is described in detail in Richards, 1987 (Richards et. al.
1987). In brief, ANP was extracted from 4 ml plasma on Sep-pak CI 8 reverse phase columns. Sep-Paks
were pre-activated with 5 ml methanol and washed with 5 ml distilled water prior to application to the
acidified (0.25 ml 2N HCl.ml"1 of plasma) plasma. Acidified plasma was centrifuged (1000 g, 4°C, 10
minutes) prior to its application to the Sep-paks. The Sep-pak cartridges were then washed with 0.1%
trifluoroacetic acid (TFA; 3x5 ml) and the adsorbed peptide was eluted with 2 ml 60% acetonitrile
(v/v) 0.1% TFA into plastic tubes. The extracts were dried down under compressed air, and
reconstituted in 0.5 ml buffer (100 mmolT1 sodium phosphate, pFI 7.4, containing 50 mmol.l1 NaCl,
0.1% w/v BSA, 0.1% w/v Triton x-100 and 50 kallikrein inhibitor units.ml'1 Trasylol). Recovery of
peptide form the Sep-paks was >80%.
Antibodies to a-hANP were raised in New Zealand white rabbits (Peninsula Laboratories).
Reconstituted plasma extract (100 ml), antibody in buffer (100 ml) at a dilution of 1/10 000, and 2 pg
1"5I-a-hANP in 50 ml of the buffer were incubated at 4°C for 24 h. Separation of free and bound ligand
was achieved by mixing with 1 ml dextran-coated charcoal. The mixture was immediately centrifuged
for 20 min at 2°C and the free label was counted. Cross-reaction of the antibody with a variety of
synthetic ANP sequences (5-28 hANP, 7-28 hANP, atriopeptins I, II, III and rat ANP) was >90%. No
significant cross-reactions with bradykinin, arginine vasopressin, angiotensins I and II or
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adrenocorticotrophic hormone (ACTH) have been reported with this method. The intra-assay CV was
3.9%.
64
Figure 2.1 Plethysmograph set-up





Study 1: Inhibition of neutral endopeptidase causes vasoconstriction of























Neutral endopeptidase (EC 3.4.24.11; enkephalinase; NEP) is a plasma membrane-bound zinc
metalloprotease that was initially isolated from renal epithelial brush border cells and cleaves peptide
substrates at the amino side of hydrophobic amino acids (Erdos & Skidgel 1989). It catalyses the
degradation of a number of endogenous vasodilator peptides, including atrial natriuretic peptide (ANP)
( Stephenson & Kenny 1987), brain natriuretic peptide (Lang et. al. 1992), C-type natriuretic peptide
(Kenny et. al. 1993), substance P (Skidgel et. al. 1984) and bradykinin (Erdos & Skidgel 1989), as well as
vasoconstrictor peptides including endothelin-1 (ET-1) (Abassi et. al. 1992) and angiotensin II (ANG
II) (Erdos & Skidgel 1989). In addition to degrading vasoactive peptides to inactive breakdown
products, NEP can also convert big ET-1 to the active peptide, ET-1 (Murphy et. al. 1994). Therefore,
the physiological actions of NEP in vivo will be the balance of its effects on the breakdown of
vasodilators and vasoconstrictors, and on the synthesis of ET-1 from big ET-1 (Figure 3.1).
NEP is inhibited by several agents, including candoxatrilat (Danilewicz et. al. 1989), thiorphan
(Schwartz et. al. 1990) and its prodrug, sinorphan (Gros et. al. 1989), and phosphoramidon (Erdos &
Skidgel 1989). ANP has potent natriuretic (De Bold et. al. 1981) and vasodilator properties (Currie et. al.
1983; Webb et. al. 1988), and inhibits activity of the renin-angiotensin-aldosterone system by reducing
both renin (Brands et. al. 1988) and aldosterone (Atarashi et. al. 1984) release. Therefore, increasing the
circulating concentrations of ANP through inhibition of NEP is an attractive therapeutic approach to a
number of cardiovascular diseases such as hypertension and heart failure (Smith et. al. 1988). However,
although NEP inhibitors increase circulating ANP concentrations in man, and cause the expected
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natriuresis (Bevan et. al. 1992; Gros et. al. 1992; Northridge et. al. 1989; Richards et. al. 1991), they do
not generally lower blood pressure in normotensive subjects (Richards et. al. 1991; Gros et. al. 1989;
O'Connell et. al. 1992; Richards et. al. 1990). Indeed, both candoxatril (Ando et. al. 1995) and
candoxatrilat (Motwani et. al. 1995) have been reported as raising blood pressure in normotensive
subjects. Although NEP inhibitors have been reported to lower blood pressure in patients with essential
hypertension (Lefrancois et. al. 1990; Ogihara et. al. 1994; Richards et. al. 1993a; Richards et. al. 1993b;
Richards et. al. 1993c; Tunny et. al. 1993), this finding has not been universal (Bevan et. al. 1992; Favrat
et. al. 1995; O'Connell et. al. 1992; Richards et. al. 1992). Thus, the therapeutic value of NEP inhibitors
in hypertension remains uncertain. In patients with heart failure, these agents do not reduce afterload
although they do reduce pulmonary capillary wedge pressure, presumably due to natriuresis (Kahn et. al.
1990; Northridge et. al. 1989).
We hypothesised that if the predominant substrates for vascular NEP were vasodilator peptides, then
local inhibition of this enzyme should cause peripheral vasodilatation. However, in previous studies
using brachial artery administration of the NEP inhibitor, thiorphan, a modest vasoconstriction had
been observed (Haynes & Webb 1994; Love et. al. 1996) suggesting accumulation of vasoconstrictor
peptides such as ANG II or ET-1. Therefore, in the present study, the effects of brachial artery
administration of a structurally different NEP inhibitor, candoxatrilat, on forearm blood flow were
examined to determine whether the vasoconstriction produced by thiorphan is a class effect of NEP
inhibitors. Whether an accumulation of ANG II was the cause of the forearm vasoconstriction
produced by thiorphan was also investigated by infusing thiorphan into the brachial artery, in the
presence or absence, of concurrent systemic angiotensin converting enzyme (ACE) inhibition.
Furthermore, whether accumulation of ET-1 was the cause of the forearm vasoconstriction by
thiorphan was examined by co-infusing an endothelin receptor A (ETA) antagonist, BQ-123, together
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with thiorphan. The effect of brachial artery administration of thiorphan in a group of hypertensive




Twenty-four healthy male subjects, and 6 hypertensive patients (BP > 160/100 mmHg) who had not yet
received any treatment, participated in these studies. None of the subjects received vasoactive or non¬
steroidal anti-inflammatory drugs in the week before each phase of the study, and all abstained from
alcohol for 24 hours and from food, caffeine-containing drinks, and cigarettes for at least 3 hours
before any measurements were made. All studies were performed in a quiet room maintained at a
constant temperature of between 22 and 25°C.
3.2.2 Drugs
Candoxatrilat (Pfizer Central Research, Sandwich, UK) and thiorphan (Sigma, Poole, UK) were
administered intra-arterially dissolved in physiological saline (0.9%; Baxter Healthcare Ltd).
(+)Candoxatrilat (UK-73,967) was used in this study; this eutomer has twice the potency as a NEP
inhibitor than the racemate, (±)candoxatrilat (UI<-69,578) (Barclay et. al. 1990) and is the active
metabolite of the orally available prodrug candoxatril. The dose of candoxatrilat (125 nmol.min"1) was
chosen to achieve forearm blood concentrations >50-fold higher than the IC50 (40 nmol.l"1) of
(+)candoxatrilat in vitro (Barclay et. al. 1990). The dose of thiorphan (30 nmol.min"1) used in this study
has been shown to produce ~20% reduction in forearm blood flow when infused via the brachial artery
(Haynes & Webb 1994). This dose is known to achieve local concentrations in forearm blood, following
brachial artery administration, > 10-fold higher than the IC50 of thiorphan (35 nmol.1"1) for NEP in vitro
(Barclay et. al. 1990), based on a forearm blood flow of 50 ml.min
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The peptide ETA antagonist, BQ-123 (Cyclo [~D-Asp-L-Pro—D-Val L-Leu D-Trp—]; American
Peptide Company, Sunnyvale, CA, USA) was administered intra-arterially (100 nmol.min"1) dissolved in
physiological saline. This dose chosen achieves local concentrations in the forearm > 10-fold higher than
the pA2 at the ETA receptor and is known to produce ~40% increase in blood flow when infused via
the brachial artery (Haynes & Webb 1994).
The ACE inhibitor, enalapril (Merck, Sharp & Dohme Ltd), was administered orally in ascending, single,
daily doses of 2.5, 5, 10 and 15 mg over a period of 4 days. This ascending dose design was used to
minimize the already low risk of hypotension. On the fifth day, subjects were admitted to the clinical
research center and, after lying supine for 30 minutes, they received 20 mg enalapril orally at 8:30 AM.
The final dose of 20 mg was chosen because it reduces plasma concentrations of ANG II to a level
close to the detection limit of radioimmunoassay 4 hours after administration (Juillerat et. al. 1990).
3.2.3 Intra-arterial administration
The left brachial artery was cannulated under local anesthesia (see Section 2.1.1). The total rate of intra¬




Blood flow was measured in both forearms by venous occlusion plethysmography using
indium/gallium-in-Silastic gauges (see Section 2.1.1).
Blood Pressure
Duplicate measurements of blood pressure in the non-infused arm were taken, which were then
averaged (see Section 2.2.1).
Plasma assays
Forty ml venous blood samples were obtained at intervals for assay of concentrations of plasma active
renin, ANG II, aldosterone, ANP and endothelin from both arms. This technique of bilateral venous
sampling, from deep veins in the antecubital fossae, together with intra-brachial artery infusion of
locally active agents has been reported previously (Plumpton et. al. 1995). Samples were collected into
chilled tubes, centrifuged at 1500^ for 20 minutes at 4°C and stored at -80°C until assay. All assays were
performed as single batches.
3.2.5 Study Design
Four single-blind studies were performed.
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Protocol 1: Intra-arterial candoxatrilat
Ten subjects participated in this single-phase, single-blind study. Subjects rested recumbent throughout.
Physiological saline was infused via the left brachial artery for 30 minutes. Candoxatrilat (125 nmol.min
') was then infused for 90 minutes. Forearm blood flow was recorded in both arms every 5 minutes.
Blood pressure was measured at 10 minute intervals.
Protocol 2: Intra-arterial thiorphan and systemicACE inhibition
Six subjects participated in this two-phase, single-blind, crossover study. In each phase, subjects were
administered orally either increasing single daily doses of enalapril (as detailed above), or matching
placebo. On the fifth day subjects were admitted to the clinical research center at 8:00 AM, and deep
veins in both antecubital fossae were cannulated with 18G intravenous cannulae (Venflon; Viggo-
Spectramed) for blood sampling. After lying recumbent for 30 minutes (8:30 AM) a venous blood
sample was taken, from the right (noninfused) arm for assays of renin, ANG II, aldosterone, ANP and
endothelin concentrations. Blood pressure was measured and enalapril 20 mg or placebo was
administered at 8:30 AM. Blood pressure was then measured at 30 minute intervals for 3.5 hours with
the subjects remaining recumbent. At 12:00 AM, physiological saline was infused via the left brachial
artery for 30 minutes. At 12:30 PM, thiorphan (30 nmol.min"1) was infused for 90 minutes, 4 hours after
administration of the final dose of enalapril or placebo. Before the start of the thiorphan infusion, a
venous blood sample was taken for aldosterone, renin and clinical biochemistry from the right
(noninfused) arm. Blood samples were also taken from both arms at the beginning and end of the
period of thiorphan infusion, for measurement of plasma ANG II, ANP and endothelin concentrations.
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Protocol 3: Intra-arterial thiorphan and intra-arterial BQ-123
Eight subjects participated in this randomised three-phase, single-blind study. Subjects rested recumbent
throughout. Physiological saline was infused via the left brachial artery for 30 minutes. In random order
and in separate occasions, at least one week apart, either thiorphan (30 nmokmin"1) or BQ-123 (100
nmol.min"1) alone, or both in combination were then infused for 90 minutes. Forearm blood flow was
recorded in both arms every 5 minutes. Blood pressure was measured at 10 minute intervals.
Protocol 4: Intra-arterial thiorphan in hypertensivepatients
Six hypertensive patients participated in this single-phase, single-blind study. Subjects rested recumbent
throughout. Physiological saline was infused via the left brachial artery for 30 minutes. Thiorphan (30
nmol.min"1) was then infused for 90 minutes. Forearm blood flow was recorded in both arms every 5
minutes. Blood pressure was measured at 10 minute intervals.
3.2.6 Data Analysis and Statistics
Plethysmography data listings were extracted from the Chart data files and forearm blood flows
calculated for individual venous occlusion cuff inflations using a template spreadsheet (Excel 4.0;
Microsoft Ltd) as described in Section 2.1.1.
Data are shown as mean ± standard error of the mean (SEM) in the figures and as mean ± SEM with
95% confidence intervals in the tables for the effects of NEP inhibition. Forearm blood flows were
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examined by repeated measures analysis of variance (ANOVA) using Statview 512+ software
(Brainpower Inc, Calabasas, Ca, USA) for the Apple Macintosh personal computer. The overall forearm
blood flow response to intra-arterial candoxatrilat and thiorphan are described in the text as the area
under the curve (AUC) (Matthews et. al. 1990) and as individual maximum responses (max).
Haemodynamic and assay measures where analysed by ANOVA and Student's /-test were appropriate
(Altman & Bland. 1996) using Statview 512^ software.
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3.3 Results
Protocol 1: Intra-arterial candoxatrilat
Brachial artery infusion of candoxatrilat did not alter systolic, diastolic or mean arterial pressure (86 ± 2
to 90 ± 2 mm Hg) or heart rate (63 ± 3 to 64 ± 3 beats per minute). Also, blood flow in the noninfused
arm did not alter significantly following infusion of candoxatrilat, confirming that drug effects were
confined to the infused arm. Brachial artery infusion of candoxatrilat caused a slowly progressive
forearm vasoconstriction, with blood flow decreasing by a mean (AUC) of 12 ± 2% and maximum of -
28 ± 3% (p=0.001; Figure 3.2) during the 90 minute infusion.
Protocol 2: Intra-arterial thiorphan and systemic ACE inhibition
There were no significant differences between plasma urea, electrolytes and creatinine concentrations at
the start of the thiorphan infusion during the placebo and enalapril phases. Heart rate and mean arterial
pressure were not significantly different at the start of thiorphan infusion in either phase, and did not
change during the intra-arterial infusion of thiorphan in either phase (Table 3.1).
Plasma active renin concentrations were higher after 4 days of treatment with enalapril than with
placebo. Plasma active renin concentration increased further 4 hours after administration of 20 mg
enalapril, with no change during the placebo phase (Table 3.1). Plasma ANG II concentration tended to
be lower after 4 days of enalapril, although this difference between phases did not reach statistical
significance (Table 3.2; p=0.09). Plasma ANG II concentrations did not change significantly during the
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placebo phase in either the infused or non-infused arms. Four hours after administration of 20 mg
enalapril, there was a substantial reduction in plasma ANG II concentration (Table 3.2). Plasma ANG II
concentration did not change further during the 90 minute thiorphan infusion in the enalapril phase in
either the infused or non-infused arms (Table 3.2). Venous aldosterone concentration was lower after 4
days of enalapril than after 4 days of placebo (Table 3.2). During both phases, aldosterone
concentration tended to decrease after four hours of supine posture. However, this decrease was only
significant after 20 mg enalapril when compared to basal (Table 3.2).
Neither oral enalapril nor intra-arterial thiorphan had any effect on plasma ANP or plasma endothelin
concentrations in either the infused or non-infused arms (Table 3.2).
Basal forearm blood flow in the infused arm tended to be lower during the enalapril phase than the
placebo phase, although this was not statistically significant (2.9 ± 0.4 and 3.7 ± 0.4 ml.lOO ml1.min 1
respectively; p=0.12). Blood flow in the non-infused arm did not change significantly following infusion
of thiorphan, confirming that drug effects were confined to the infused arm. Brachial artery
administration of thiorphan caused a slowly progressive forearm vasoconstriction, with blood flow
decreasing during both the enalapril phase (mean 17 ± 6%; max 33 ± 7%; p=0.05) and placebo phase
(mean 13 + 3%; max 24 ± 2%; p=0.006). The reductions in blood flow were similar during either phase
(p=0.6; Figure 3.3).
Protocol 3: Intra-arterial thiorphan and intra-arterial BQ-123
Brachial artery administration of BQ-123 alone caused a progressive forearm vasodilatation (mean 33 +
3%; max 47 ± 9%; p=0.0001) whereas thiorphan caused a slowly progressive vasoconstriction (mean -
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14 ± 1%; max -22 ± 4%; p=0.0001). Co-infusion of BQ-123 and thiorphan caused a vasodilatation
(mean 32 ± 2%; max 48 ± 6%; p=0.0001) which was not different from that observed with BQ-123
alone (p=0.98; Figure 3.4).
Protocol 4: Intra-arterial thiorphan in hypertensivepatients
In hypertensive patients, brachial artery administration of thiorphan caused a slowly progressive forearm
vasoconstriction (mean -10 ± 2%; max -20 ± 3%; p=0.0001). This was not significantly different from
that observed in the healthy volunteers in the third study (p=0.39; Figure 3.5).
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3.4 Discussion
These studies have shown that the specific NEP inhibitors, candoxatrilat and thiorphan, cause slowly
progressive vasoconstriction when given by direct brachial artery infusion to healthy subjects and
patients with essential hypertension. The vasoconstriction caused by thiorphan was not reversed by
systemic ACE inhibition but was abolished by endothelin receptor antagonism. Our findings are
unlikely to be due to other actions of these agents because both candoxatrilat (Danilewicz et. al. 1989;
Northridge et. al. 1989) and thiorphan (McMahon et al. 1991) are highly specific for NEP. Furthermore,
the finding that two structurally independent inhibitors of NEP produce vasoconstriction strongly
suggests that this is a class effect of NEP inhibition on human resistance vessels. It is possible that
different effects may be obtained in other blood vessels, although responses in forearm resistance
vessels are generally thought to be broadly representative of those in other vascular beds (Webb 1995).
Our findings have potential implications both for the physiological role of NEP and for the therapeutic
use ofNEP inhibitors.
Although it was initially thought that the most important site of natriuretic peptide metabolism by NEP
was the kidney (Stephenson & Kenny 1987), candoxatrilat is just as effective in reducing clearance of
ANP in nephrectomized animals (Barclay et. al. 1991), implying other, non-renal, sites of action. NEP is
now known to be expressed in blood vessels, by both endothelial (Graf et. al. 1995) and vascular
smooth muscle cells (Dussaule et. al. 1993). Despite the clear evidence for vascular generation and
metabolism of natriuretic peptides, these studies have demonstrated that local NEP inhibition causes
vasoconstriction rather than vasodilatation. This finding implies that, under physiological conditions,
vasoconstrictor peptides, such as ANG II and ET-1, are more important substrates for vascular NEP
than dilator substances, such as the natriuretic peptides and bradykinin (Figure 3.1). Flowever, our
finding that brachial artery administration of thiorphan produces forearm vasoconstriction in the
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presence of substantial systemic ACE inhibition implies that ANG II accumulation is not responsible
for the observed vasoconstriction. In addition, ANP blocks activity of the renin-angiotensin system by
reducing renin release and blocking aldosterone secretion, so ANG II generation is likely to be
decreased by NEP inhibition.
The vasoconstriction to candoxatrilat and thiorphan was slowly progressive, which is more in keeping
with an effect of ET-1 than ANG II, based on the known rate of onset of forearm vasoconstriction
after brachial artery infusion of these peptides (Brands & Freeman 1988). This is supported by a recent
study in which systemic oral doses of candoxatril in healthy men produced an increase in both systolic
blood pressure and venous plasma endothelin concentration (Ando et. al. 1995). In another recent
study, systemic administration of candoxatrilat in healthy subjects produced a significant increase in
systolic blood pressure (Motwani et. al. 1995). However, because this rise was prevented by pre-
treatment with enalapril, it was suggested that the increase in blood pressure was caused by potentiation
of ANG II. Our findings do not support this conclusion. Indeed, in our study thiorphan produced
arterial vasoconstriction in the presence of systemic ACE inhibition, despite ANG II concentrations
being very low. Furthermore, no increase in ANG II concentrations was detected in venous blood
draining the infused arm during the placebo phase of our study suggesting that NEP inhibition does not
cause an accumulation ofANG II.
No significant fall in blood pressure after 20 mg enalapril orally was detected despite the very low
concentrations of ANG II produced. However, our study was not designed to specifically measure
changes in systemic haemodynamics. The hypotensive effect of enalapril would be expected to have
been greatest when subjects were being prepared for the intra-arterial stage of the study. This involved
subjects standing to pass urine and having the blood pressure cuff repositioned over the rapid inflation
cuffs required for forearm plethysmography, as well as insertion of an intra-arterial needle.
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In this study, enalapril had no effects on plasma ANP concentrations. This is in agreement with other
published reports (Doorembos & van Brummelen 1989; Motwani et. al. 1995) Intra-arterial thiorphan
did not produce a detectable increase in ANP concentrations in venous blood draining the infused arm.
However, any changes in local ANP concentrations are likely to be small and may have been below the
sensitivity of the assay. In addition, not all studies of acute NEP inhibition have demonstrated an
increase in ANP concentrations (Ando et. al. 1995; Favrat et. al. 1995; O'Connell et. al. 1993). ANP may
also be metabolised by an aminopeptidase which is insensitive to thiorphan (Olins et. al. 1987).
Although incomplete local NEP inhibition is possible, this is highly unlikely because the doses of both
candoxatrilat and thiorphan used were chosen to achieve local blood concentrations in the forearm
>50-fold and > 10-fold higher higher than the IC50 of (+)candoxatrilat and thiorphan respectively for
ANP in vitro (Barclay et. al. 1990).
Consistent with earlier work (Uemasu et. al. 1993), systemic ACE inhibition with enalapril had no effect
on plasma endothelin concentrations. In addition, intra-arterial thiorphan did not increase plasma
endothelin concentrations in samples collected from the infused arm. However, endothelin produced by
endothelial cells is preferentially secreted abluminally (Wagner et. al. 1993) and inhibition of local
endothelin degradation may not have resulted in increased plasma endothelin concentrations.
Furthermore, any measurable increase in plasma endothelin concentrations is likely to be rapidly
reduced through tissue receptor binding (Plumpton et. al. 1995). Therefore, the absence of any
detectable rise in plasma endothelin does not exclude local accumulation of the peptide and it is still
possible that decreased ET-1 breakdown is the cause of the vasoconstriction produced by NEP
inhibitors.
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ET-1 mediates vasoconstriction primarily by effects on the vascular smooth muscle ETA receptor
(Davenport & Maguire. 1994). The selective ETA receptor antagonist, BQ-123 abolishes the
vasoconstriction produced by thiorphan. This provides strong evidence that accumulation of ET-1,
resulting from an inhibition of its degradation, mediates the vasoconstriction caused by local NEP
inhibition. Nevertheless, it is also possible that accumulation of an as yet undiscovered vasoconstrictor
may contribute to the observed vasoconstriction, although its abolition by BQ-123 makes this unlikely.
In clinical trials, NEP inhibitors have been shown to cause a natriuresis and diuresis (Gros et. al. 1989;
Northridge et. al. 1989). However, a reduction in blood pressure has not been clearly demonstrated in
normotensive subjects (O'Connell et. al. 1992; Gros et. al. 1989; Richards et. al. 1991) and two studies
have even reported an increase in blood pressure (Ando et. al. 1995; Motwani et. al. 1995) despite the
potent vasodilator actions of the natriuretic peptides (Struthers 1994; Webb et. al. 1988). Also, several
studies on hypertensive patients (Bevan et. al. 1992; Favrat et. al. 1995; O'Connell et. al. 1992; Richards
et. al. 1992 have not demonstrated a reduction in blood pressure. Furthermore, a recent study in
patients with CHF showed that candoxatrilat further increased systemic vascular resistance in these
patients (Kentsch et. al. 1996). Our results help to explain this apparent contradiction. The
haemodynamic effects of systemic NEP inhibition will depend on the balance between its cardiac, renal
and vascular actions. These studies have shown that local NEP inhibition causes forearm
vasoconstriction in healthy subjects and, of greater clinical relevance that this effect is also occurs in
untreated essential hypertensive patients. Thus, peripheral vasoconstriction may play an important role
in counteracting the anti-hypertensive actions ofNEP inhibition.
Our study shows that the vasoconstriction produced by NEP inhibitors may be mediated by ET-1 or
other vasoconstrictor peptides. Given that systemic NEP inhibition has been shown to increase venous
endothelin concentrations (Ando et. al. 1995), it is possible that the combination of NEP inhibition and
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endothelin antagonism may be useful therapeutically. Indeed, phosphoramidon, a combined endothelin-
converting enzyme and NEP inhibitor, is known to produce substantial vasodilatation when infused
intra-arterially in humans (Haynes & Webb. 1994; Love et. al. 1996), and can lower blood pressure in
normotensive and hypertensive rats (McMahon et. al. 1991). Nevertheless, even without reducing blood
pressure, NEP inhibition may offer therapeutic benefits in hypertension and heart failure. For example,
infusion of ANP causes sympathoinhibition in man (Ando et. al. 1995). In addition, NEP inhibitors
appear to possess favourable anti-mitogenic effects in models of left ventricular hypertrophy (Monopoli
et. al. 1992) and atherosclerosis (Kugiyama et. al. 1993). Such effects would need to be counterbalanced
against potential mitogemc actions of ET-1 (Gray & Webb. 1996).
In conclusion, local inhibition of NEP causes slowly progressive vasoconstriction in healthy subjects
and essential hypertensive patients, suggesting that the predominant physiologic substrates for vascular
NEP are vasoconstrictor peptides. The slowly progressive nature of the vasoconstriction together with
the finding that it is not blocked by systemic ACE inhibition, but is abolished by endothelin antagonism,
supports accumulation of ET-1 as the cause. Vasoconstriction produced by NEP inhibitors may help to




Table 3.1 Systemic haemodynamics after oral enalapril and intra-arterial thiorphan
Header:
Heart rate, blood pressure, plasma active renin and aldosterone concentrations (mean ± SEM) before
(8:30 AM; basal) and 4 hours after (12:30 PM) oral administration of placebo or enalapril 20 mg.
Footer:
CI indicates confidence intervals.
*p = 0.05 v. basal (8:30 AM)
f p = 0.05 v. placebo phase
£ p = 0.005 v. placebo phase
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3.6 Figure Legends
Figure 3.1 Actions of neutral endopeptidase
The enzyme neutral endopeptidase 24.11 (NEP) catalyses the metabolism of the vasoconstrictor
peptides endothelin-1 (ET-1) and angiotensin II (ANG II), as well as the metabolism of several
vasodilator peptides, including bradykinin (BI<), atrial, brain and C-type natriuretic peptides (ANP, BNP
and CNP respectively) and substance P (SP). NEP is also involved in the enzymatic conversion of big
ET-1 to its active form, the vasoconstrictor peptide, ET-1. The balance of effects of NEP inhibition on
vascular tone will, therefore, depend on whether the predominant substrate(s) degraded by NEP are
vasodilators or vasoconstrictors and in the extent ofNEP involvement in the processing of big ET-1.
Figure 3.2 Intra-arterial candoxatrilat
Effect of brachial artery administration of the NEP inhibitor, candoxatrilat (125 nmol.min"1 for 90
minutes), on forearm blood flow in 10 healthy, male volunteers. Candoxatrilat produced a slowly
progressive vasoconstriction confined to the infused forearm (p=0.001).
Figure 3.3 Intra-arterial thiorphan and systemic ACE inhibition
Effect of brachial artery administration of the NEP inhibitor, thiorphan (30 nmol.min"1), on forearm
blood flow after oral placebo (o) or oral enalapril (•) in 6 healthy, male volunteers (see text for details).
Thiorphan produced a slowly progressive vasoconstriction both during the placebo (p=0.05) and
enalapril phases (p=0.01), with no significant difference between the two phases (p=0.6).
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Figure 3.4 Intra-arterial thiorphan and BQ-123
Effect of brachial artery administration of the NEP inhibitor, thiorphan (o; 30 nmol.min"1), the
endothelin receptor antagonist, BQ-123 (•; 100 nmol.min"1) and co-infusion of both agents (□) on
forearm blood flow. Thiorphan produced a slowly progressive vasoconstriction (p=0.0001) whereas
BQ-123 caused a slowly progressive vasodilatation (p=0.0001). Co-infusion of BQ-123 and thiorphan
produced a vasodilatation (p=0.0001) not significantly different from that produced by BQ-123 alone
(p=0.98).
Figure 3.5 Intra-arterial thiorphan in hypertensive patients
Effect of brachial artery administration of the NEP inhibitor, thiorphan (30 nmol.min"1), on forearm
blood flow in 6 hypertensive patients. Thiorphan produced a slowly progressive vasoconstriction

















Placebo phase Enalapril phase
Time Time
8:30 AM 12:30 PM 8:30 AM 12:30 PM
58 ± 3 (51 to 65) 57 ± 3 (47 to 63) 56 ± 3 (49 to 63) 61 ± 3 (52 to 69)
126 ±6 (110 to 130 ±6 (113 to 124 ±7 (104 to 124 ± 7 (104 to 142)
141) 146) 142)
63 ± 2 (57 to 69) 69 ± 5 (55 to 84) 57 ± 2 (51 to 62) 65 ± 2 (59 to 71)
84 ± 3 (75 to 92) 89 ± 5 (55 to 84) 79 ± 3 (70 to 87) 85 ± 4 (75 to 94)
22 ±4 (12 to 25) 19 ±2 (12 to 25) 75 ± 9 $ (52 to 99) 136 ±12*$ (106 to
166)
15.8 ± 2.5 (8.9 to 11.4 ± 1.3 (8.0 to 12.3 ± 1.5f (8.3 to 6.9 ± 0.7*$ (5.0 to
21.9) 14.9) 16.1) 8.8)
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Study 2: Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced
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Endothelin-1, which was first identified by Yanagisawa and colleagues (Yanagisawa et at 1988), is a well
characterised, potent and sustained vasoconstrictor and pressor agent involved in the endothelium-
mediated regulation of vascular tone (Haynes & Webb, 1998). Two ET receptor subtypes have been
identified at a molecular level and characterised pharmacologically in blood vessels. ETA receptors (Arai
et al. 1990) have higher affinity for ET-1 than ET-3, are found on vascular smooth muscle cells, and
mediate vasoconstriction. ETB receptors have equal affinity for ET-1 and ET-3 (Sakurai et al. 1990) and
are found on vascular endothelial cells, where they mediate endothelium dependent vasodilatation (De
Nucci et al. 1988; Tsukahara et al. 1994). ETB receptors are also present on vascular smooth muscle cells,
where they may contribute to vasoconstriction (Clozel et al. 1992; Reizebos et al. 1994; Seo et al. 1994;
Tschudi & Luscher, 1994).
Local studies in human forearm resistance vessels using phosphoramidon, an endothelin converting
enzyme inhibitor, and BQ-123, a selective ETA receptor antagonist, first demonstrated the importance
of ET-1 in maintaining basal resistance vessel tone, in large part through an action on the ETA receptor
(Haynes & Webb, 1994). These observations have since been confirmed by others (Berrazueta et al.
1997; Verhaar et al. 1998). Responses in the forearm resistance vessels are usually predictive of those in
the systemic circulation (Webb, 1995), so these data suggested that systemic ETA receptor antagonism
would produce systemic vasodilatation. Recently, however, acute systemic administration of the
selective ETA antagonist, BQ-123, was reported to have no effect on systemic haemodynamics
(Schmetterer et al. 1998; Montanari et al. 2000).
We hypothesised that a systemic haemodynamic effect of ETA receptor blockade was not seen in these
studies, in which subjects received co-infusions of ET-1 (2.5 ng kg(-l) min(-l) for 120 min) or placebo
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and BQ-123 (15 microg min(-l) for 60 min and subsequendy 60 microg min(-l) for 60 min) or placebo
(Schmetterer et al 1998) or 0.125 nmol. Kg (Montanari et al. 2000), because the doses of BQ-123 used
provided insufficient ETA receptor blockade to affect blood pressure. In addition, because healthy
subjects have a number of reflex mechanisms that serve to defend blood pressure, we hypothesised that
an important effect on systemic vascular resistance might have been missed by measurement of blood
pressure alone. We also hypothesised that systemically effective ETA antagonism with BQ-123 might be
associated with inhibition of the vasoconstriction to exogenous doses of infused ET-1 sufficient to
cause modest effects on basal forearm vascular resistance. We, therefore, undertook two studies. First,
we assessed the haemodynamic effects of increasing doses of BQ-123, using bioimpedance
cardiography, with the aim of achieving a high degree of ETA selective receptor blockade. Second, we
examined whether haemodynamically active doses of BQ-123 would antagonise the response to
exogenous ET-1, by infusion of local doses of ET-1 into the forearm circulation, after administration of




Five healthy men (age range 18-30 years) were recruited to each of the 2 studies, which were
performed in the Clinical Research Centre at the Western General Hospital, Edinburgh, with the
approval of the local research ethics committee and the written informed consent of each subject. The
investigations conformed to the principles outlined in the Declaration of Helsinki. No subject received
vasoactive medication in the week before each phase of the study, and all subjects were asked to abstain
from alcohol, nicotine and caffeine-containing products for 24 h and from food for at least 4 h before
any measurements were made. All studies were performed from 8.30 am, in a quiet room kept at a
controlled temperature (22-24°C).
4.2.2 Drugs
BQ-123 (Clinalfa AG, Laufelfmgen, Switzerland, molecular weight 632.7) at doses ranging from 100 -
3000 nmol min 1 was used as a selective ETA receptor antagonist, with 2,500 lower affinity for the ETB
receptor (IC50 ETA of 7.3 nM against IC50ETB of 18 pM) (Ihara et al. 1992). The dose range was selected
from previous studies investigating the local effects of BQ-123, which suggested that 100 nmol min 1 is
the threshold around which systemic effects might be observed (Flaynes & Webb, 1994). BQ-123 was
dissolved in physiological saline (0.9%, Baxter Healthcare Ltd, Thetford, UK). Saline was also used as
placebo. BQ-123 and placebo were administered in a double-blind manner and infused intravenously at
a constant rate of 1 ml min 1 for 15 min via an 18 standard wire gauge (SWG) cannula sited in the right
antecubital fossa (Study 1) or right distal forearm (Study 2).
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ET-1 (Clinalfa AG, molecular weight 2492) was dissolved in physiological saline to a concentration of 5
pmol min 1 (Haynes & Webb, 1994) and infused into the left brachial artery via a 27 SWG steel cannula
at a constant rate of 1 ml min 1 for a total of 90 min as described in the methods section 2.1.
All solutions were prepared from sterile stock solutions on the day of the study. For the forearm studies
1% lignocaine (Astra Pharmaceuticals, Stockholm, Sweden) was used as a local anaesthetic.
4.2.3 Systemic haemodynamics
Haemodynamic measurements were made at 10 min intervals from 30 min pre-dose until 60 min post-
dose, then at 30 min intervals until 2 h, then hourly until 4 h post-dose. BP was recorded in duplicate in
the right arm as described in the methods section 2.2. CO and heart rate (HR) were recorded using
bioimpedance technique as described in the methods section 2.3.
4.2.4 Forearm Flood Flow
Blood flow was measured in both forearms by venous occlusion plethysmography as described in the
methods section 2.3.
4.2.5 Plasma ET-1, big ET-1 and BQ-123
During Study 1, 10 ml of venous blood was obtained from a cannula inserted in the left antecubital vein
before and at 5, 15 and 240 min after BQ-123 infusion for measurement of plasma ET-1 and big ET-1.
In addition, during the 300 and 1000 nmol min 1 phases, sub-aliquots of the samples were used for
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plasma BQ-123 assay. Plasma ET-1 and big ET-1 concentrations were measured as described in the
methodology section (2.6.4).
4.2.4 Study design
4.2.4.1 Systemic haemodynamic study
This was a double-blind, placebo-controlled, balanced 5-way crossover study in 5 subjects, investigating
the responses to four doses of BQ-123 (100, 300, 1000 and 3000 nmol min ]) and placebo (0.9% saline).
An ascending dose regimen was followed, allowing safety and tolerability of lower doses to be assessed
before proceeding. Total doses of BQ-123 administered were 1.5, 4.5, 15 and 45 pmol (or 0.95, 2.84, 9.5
and 28.4 mg). The order of the placebo dose was randomly allocated so that each subject received it on
a different visit. Each visit was separated by at least 5 days. Subjects rested supine for 20 min before any
haemodynamic measurements, and baseline measures were then made in the 30 min before study drug
administration.
4.2.4.2 ET-1 challenge study
This was a double-blind, placebo-controlled, 3-way crossover study in 5 subjects (3 of whom
participated in the systemic study), investigating the effects of intra-arterial ET-1 on forearm blood flow
(FBF), after treatment with either 300 or 1000 nmol min1 of BQ-123 or placebo. After baseline
infusion of saline for 30 min, subjects received a 15 min intravenous infusion of BQ-123 (300 or 1000
nmol min ') or placebo via a cannula in the right forearm, followed immediately by an intra-arterial




Data were stored and analysed using the Microsoft Excel data analysis package (Excel 5.0, Microsoft
Ltd). Blood pressure data at each time point were calculated as the mean of two recordings and
represented as mean arterial pressure (MAP), calculated as diastolic BP + 1/3 pulse pressure.
Bioimpedance data at each time point were calculated as the mean of four recordings. Data were
corrected using body surface area to give cardiac index (CI) for direct comparison of subjects. Systemic
vascular resistance index (SVRI) was calculated by dividing MAP by CI and expressed in arbitrary units.
Baseline data were calculated as the mean of -10 min and 0 min recordings. Haemodynamic data are
expressed as placebo-corrected percentage change from baseline ± SEM. Statistical analysis was
performed on untransformed data. Responses were examined by repeated measures analysis of variance
(ANOVA) and Bonferroni correction was applied to examine significance at each time point. Statistical
significance was taken at the 5% level.
Using MAP & SVRI measurements from a previous placebo-controlled study over 4 h (Strachan et at
1999), the study was calculated to have a power of ~90% to detect a 15% change in MAP and 20%
change in SVRI (p=0.05) with 5 subjects. The number of subjects was agreed with the local ethics
committee on that basis.
4.2.5.2 ET-1 challenge
Plethysmography data listings were extracted from the chart data files and forearm blood flows
calculated for individual venous occlusion cuff inflations using a template spreadsheet (Excel 4.0;
Microsoft Ltd. FBF results are shown as the percentage change from basal values in the ratio of blood
flow between infused and non-infused arm. Data were examined by repeated measures analysis of
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variance (ANOVA) and Bonferroni correction was applied to examine significance at each time point.
Statistical significance was taken at the 5% level.
From FBF measurements in a previous study using ET-1 at 5 pmol min 1 (Newby et al. 1998b), the
study was calculated to have a power of 99% to detect abolition of the vasoconstriction response to





All 5 subjects (mean age 26 ± 2 years) completed all parts of the study. No adverse effects of treatment
were reported.
Plasma ET-1 and big ET-1
Baseline values of plasma ET-1 and big ET-1 concentrations ranged from 4.4 to 5.2 pg ml1 and 25 to
42 pg ml1 respectively. There were no significant differences between baseline plasma ET-1 or big ET-
1 concentrations in any phase of the study. Neither ET-1 nor big ET-1 changed significantly following
treatment with any dose of BQ-123 or placebo (Table 1A & IB).
Plasma BQ-123 concentrations
Plasma concentrations of BQ-123 were undetectable with both doses at baseline. For 300 nmol min 1
BQ-123, mean plasma concentrations were 126 ±11 nmol 11 at 5 min rising to 174 ± 20 nmol 11 at 15
min. For 1000 nmol min 1 BQ-123, they were 424 ± 33 nmol 11 and 510 ± 64 nmol 11 respectively (ETA
receptor IC50 7.3 nM; ETB receptor IC50 18 nM) (Ihara et al. 1992). BQ-123 was no longer detectable in
the plasma by 4 h at either dose.
Elaemodynamicparameters
Baseline measurements for haemodynamic parameters were similar during all treatment periods (Table
2). After BQ-123 administration, changes were apparent in all parameters by the first measurement at 10
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min. Maximal changes occurred between 40 and 60 min, with a prolonged effect occurring at the 2
highest doses, excepting changes of heart rate, which were maximal at 15 min.
MAP decreased in a dose-dependent fashion. This was statistically significant at 300, 1000 and 3000
nmol min"1 BQ-123 (300 nmol min"1: ANOVA p<0.05 vs. placebo, 1000 & 3000 nmol min p<0.01
vs. placebo) with a maximum mean placebo-corrected reduction of 12.4 ± 3.5% after 3000 nmol min \
Placebo corrected SVRI also decreased in a dose dependent fashion. This decrease was significant for all
doses of BQ-123 (ANOVA p<0.01 vs. placebo). The maximum decrease in SVRI (23.3 ± 4.3%)
occurred with 3000 nmol min 1 of BQ-123 (Table 3 & Figure 1).
CI and HR increased significantly at all doses (p<0.01; ANOVA, Table 3 & Figure 1).
4.3.2 ET-1 challenge
Subjects who received placebo followed by local infusion of ET-1 developed a slow onset progressive
vasoconstriction in the infused arm compared to the non-infused arm (maximum reduction in FBF: -48
± 10% at 90 min). This response was attenuated by 300 nmol min 1 BQ-123 (-27 ± 8% at 90 min p>0.5
vs. placebo) and abolished by 1000 nmol min 1 BQ-123 (-8% ± 3%, p<0.01 vs. placebo, Figure 2).
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4.4 Discussion
We have shown, in healthy humans that BQ-123 causes substantial systemic vasodilatation, associated
with a small but significant reduction in arterial BP. A dose-dependent effect was observed, with litde
additional effect occurring above 1000 nmol min \ This work confirms the importance of the
endothelin system, and of the vascular ETA receptor in controlling vascular tone and BP (Haynes &
Webb, 1998), and is in accord with the results of previous local forearm infusion studies (Haynes &
Webb, 1994; Berrazueta et al. 1997; Verhaar et al. 1998).
We have several reasons for concluding that the effects on vascular tone and BP are mediated by the
ETa receptor. Measured BQ-123 concentrations in plasma at both 300 and 1000 nmol min1 were
substantially greater than the IC50 for BQ-123 at the ETA receptor. Even so, at 1000 nmol min1 the
plasma concentration of 510 nmol 1 , was more than 35 fold lower than the IC50 for the ETB receptor
(18 uM), consistent with effective but selective ETA receptor blockade (Ihara et al. 1992). In addition,
there is a substantial body of evidence that the ETB receptor is a clearance receptor for ET-1 (Fukuroda
et al. 1994; Ozaki et al. 1995; Dupuis et al. 1996) and that agents that block the ETB receptor in vivo
cause increases in plasma ET-1 concentrations (Haynes et al. 1996; Weber et al 1996; Sutsch et al. 1998;
Strachan et al. 1999). In contrast, in this study, there was no significant increase in either big ET or ET-1
plasma concentration at any dose of BQ-123 (Tables 1A & IB). Finally, we have previously shown that
the net effect of systemic ET0 receptor blockade is to cause systemic vasoconstriction, and therefore,
we would anticipate that any ETB blockade would attenuate the vasodilatation associated with ETA
blockade. Indeed, this effect may contribute to the lack of further vasodilatation at the highest dose of
BQ-123, which was associated with a tendency for a rise in plasma ET-1 concentration, also consistent
with a threshold effect on the ETB receptor at this dose. Doses sufficient to lower BP (300 & 1000
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nmol min ') also antagonised the forearm vasoconstriction to brachial artery administration of ET-1 and
in keeping with its sub-maximal effect on SVRI, the lower dose of BQ-123 (300 nmol min1) only
partially antagonised forearm vasoconstriction to ET-1. Of note, however, in the presence of a higher
degree of ETA blockade, exogenous ET-1 failed to produce vasodilatation. This likely reflects the local
balance of dilator and constrictor effects mediated by endothelial and vascular smooth muscle ETB
receptors.
Although previous studies in healthy men (Schmetterer et al. 1998; Montanari et al. 2000) failed to
demonstrate a significant haemodynamic effect of BQ-123, their doses were substantially lower at 23.7
nmol/min for 60 min, followed by 94.8 nmol/min for 60 min (Schmetterer et al. 1998) and ~9
nmol/min for 90 min (Montanari et al 2000). These should be compared with 100 nmol/min BQ-123
for 15 min as the threshold dose for a systemic haemodynamic effect in our studies. In addition, both
other studies measured BP but not SVRI, whereas, from the current study, the latter was a more
powerful measure of the vascular effect of BQ-123, underlining the importance of this measurement in
detecting modest haemodynamic influences. In this regard, other published studies in humans with
endothelin antagonists do appear to show modest (~10 mmPIg) reductions in BP, with both bosentan
(mixed ETA/ETB) (Weber et al. 1996) and ABT-627 (ETA selective) (Verhaar et al 2000). In the latter
study, although systemic haemodynamics were only recorded at 30 min and 8 hours after dosing, SVR
was measured and significant effects on this parameter were found in both acute and chronic dosing.
In the current study, there was an increase in heart rate similar to that observed in other acute studies
(Weber et al. 1996; Wenzel et al. 1998). These effects are not generally seen in chronic dosing studies
with endothelin antagonists in patients with either hypertension or heart failure (Krum et al. 1998;
Sutsch et al. 1998). For this reason, the effects are probably mediated through the activation of a
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cardiopulmonary reflex response to systemic vasodilatation rather a direct chronotropic effect on the
heart.
Although the total number of subjects studied was low (n=5), the power of the study was sufficient to
allow clear conclusions to be drawn. Given the limited experience with BQ-123 at these systemic doses,
there were safety reasons for keeping the number of subjects to a minimum. In this regard, it is
reassuring to note that, despite substantial systemic vasodilatation, and significant lowering of the MAP,
no side effects were observed or reported by the subjects.
In conclusion, this study with BQ-123 demonstrates that systemic ETA receptor antagonism causes
substantial peripheral vasodilatation and modest lowering of BP, consistent with an important role for
the endothelin system in the maintenance of vascular tone in man. It remains to be seen, in direct
comparison between selective ETA and mixed ETA/B receptor antagonists, which of the therapeutic
approaches will offer the greater haemodynamic benefit in specific clinical indications.
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Table 4.1 - Baseline data - absolute values
BQ-123 MAP SVRI CI HR
nmol/min (mmHg) (L/min/m2) (bpm)
Placebo 78.9 ± 1.5 22.7 1.3 3.52 ± 0.21 64.2 ± 6.6
100 79.2 ±2.3 21.9 ± 1.7 3.69 ± 0.25 57.1 ± 5.2
300 80.8 ±3.5 21.8 ±1.8 3.80 ±0.31 63.9 ±6.6
1000 78.2 ±2.1 22.5 ± 2.9 3.63 ± 0.38 54.5 ±4.8
3000 78.6 ± 3.3 23.5 ± 2.2 3.45 ± 0.35 57.3 ± 5.9
Anova BL P=0-96 P=0.98 P=0.89 P=0.69
data
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Table 4.2 - Haemodynamic changes after BQ-123 administration.
Results given are maximum placebo corrected percentage change from baseline ± SEM
p<0.05 vs placebo, ^p<0.01 vs placebo: ANOVA + Bonferroni correction
BQ-123 MAP SVRI CI HR
(nmol/min) (mmHg) (L/min/m2) (bPm)
100 -4.8 ±2.6% -15.8 ±7.6% 14.3 ± 8.9% 23.8 ± 13.4%+
(-4.0 ± 2.5) (-3.9 ± 2.1) (0.49 ± 0.32) (12.1 ± 6.5)
300 -6.8 ±3.6% -20.6± 3.0%* 13.0 ± 2.2%* 11.8±4.4%
(-5.4 ± 2.8) (-4.5 ± 0.7) (0.47 ± 0.07) (6.8 ± 2.4)
1000 -8.2 ± 3.1%' -22.7 ± 5.2%t 17.9 ± 5.7%t 20.0 ± 5.9%t
(-6.4 ±2.4) (-5.4 ±1.9) (0.59 ± 0.16) (11.6 ± 3.0)
3000 -12.4 ± 3.5%t -23.3±4.3%t 12.7 ± 1.6% 18.7 ± 6.8%*

























Change in MAP against time for ascending doses of BQ-123; change in SVRI against time for ascending
doses of BQ-123; change in CI against time for ascending doses of BQ-123; change in HR against time
for ascending doses of BQ-123.
Ill
Figure 4.2
Figure 4.2 - Graph illustrating response in forearm blood flow to intra-arterial ET-1, when pre-treated
with placebo or BQ-123 (either 300 or 1000 nmol min 1 for 15 min).
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Study 3: Systemic blockade of the ETB receptor increases peripheral vascular













The importance of endothelin-1 (ET-1) as a mediator of basal vascular tone in vivo in man has been
demonstrated by local (Haynes & Webb; Haynes et al. 1996; Verhaar et al. 1998) and systemic (Haynes
et al. 1996) vasodilatation in response to endothelin receptor antagonism. The potent vasoconstrictor
effects of ET-1 (Yanagisawa et al. 1988; Clarke et al. 1989), combined with the increased plasma
concentrations of ET-1 associated with cardiovascular diseases including heart failure (Pacher et al.
1993) and renal failure (Koyama et al. 1989), provide strong evidence to support a functional role for
ET-1 in the development and maintenance of the increased peripheral vascular resistance associated
with these conditions.
The vascular effects of ET-1 are mediated by two distinct receptors; the ET-1 selective ETA receptor
(Arai et al. 1990) and the non-isopeptide selective ETB receptor (Sakurai et al. 1990). The sustained
vasoconstrictor effects of ET-1 are predominantly mediated by the ETA receptor, although vascular
smooth muscle ET„ receptors have also been described (Davenport et al. 1993) and may, under some
circumstances, contribute to ET-1 mediated vasoconstriction in animal models (Clo2el et al. 1992) and
humans in vivo (Haynes et al. 1995). ETB receptors were first described on endothelial cells, where they
act to modulate the vasoconstrictor effects of ET-1 through generation of nitric oxide (Tsukahara et al.
1994) and prostacyclin (De Nucci et al. 1988) The ETB receptor also has a role in the clearance of ET-1
from the circulation (Fukuroda et al. 1994), although the exact site of the clearance receptor remains to
be confirmed. The contribution of the vascular ETB receptor to the recognised endogenous ET-1
mediated constrictor tone depends on the balance between the ETB receptor mediated effects of
vasodilatation, vasoconstriction and ET-1 clearance.
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Local vasoconstriction to ETB receptor agonists has been described in healthy volunteers (Haynes et al.
1995; Strachan et al. 1995) and in patients with heart failure (Love et al. 1996). However, more recently,
vasoconstriction following local administration of the selective ETB receptor antagonist BQ-788
(Ishikawa et al. 1994) has been described in healthy volunteers (Verhaar et al. 1998) and in patients with
heart failure (Love et al. 1996b). The results with antagonists are particularly important as they indicate
that the endogenous effect of vascular ETB receptor stimulation in vivo favours vasodilatation. Indeed,
hypertension has been described following administration of systemic doses of the selective ETB
receptor antagonists Al 92621 in rats and BQ-788 in rabbits in vivo, as well as in rescued ETB knockout
mice (Gratton et al. 1997; Webb et al. 1998). The vasoconstrictor effects of ETB antagonism may result
from direct blockade of an endothelial ETB receptor mediated dilator tone or indirectly from
displacement of endogenously generated ET-1 to vasoconstrictor ETA receptors, or as a result of
reduced clearance of ET-1 by vascular ETB receptors. Confirmation of the balance of the vascular
effects mediated by the ETB receptor in different circumstances is important in understanding the
physiology of the endothelin system, and in determining whether selective ETA receptor antagonists or
combined ETA/B receptor antagonists are likely to be more effective vasodilator agents in the clinical
setting. Although both selective and non-selective endothelin receptor antagonists have demonstrated
vasodilator effects in healthy subjects (Haynes & Webb; Llaynes et al. 1996), in patients with heart
failure (Cowburn et al. 1998; Kiowski et al. 1995) and in patients with hypertension (Ferro et al. 1996;
Krum et al. 1998), the question of whether selective ETA or combined ETA/B receptor antagonism will
be ofmore benefit as vasodilator therapy remains to be clarified.
ETa receptor mRNA can be detected in many tissues, with the highest expression in aorta, heart and
kidney. The ETA receptor predominates in vascular smooth muscle (Arai et al. 1990), while ETB
receptor mRNA is most abundant in endothelial cells (Hosada et al. 1990; Molenaar et al. 1993).
Vascular smooth muscle constriction is mediated predominantly by ETA receptors, modified by release
of relaxing factors from the endothelium, partly through stimulation of ETB receptors. ETB receptor
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mRNA is also detectable in vascular smooth muscle cells (Winkles et al. 1993) and ETB selective
agonists can evoke constriction in vitro (Shetty et al. 1993; Sumner et al. 1992) and pressor responses in
vivo (Clozel et al. 1992; Williams et al. 1991), suggesting the presence of ETB receptors that mediate
constriction of vascular smooth muscle cells (Figure 1.4).
In isolated human blood vessels, the ETA receptor subtype primarily mediates constriction in large
calibre arteries (Davenport et al. 1994), but the relative functional role of ETB receptors is greater in
small calibre arteries (Takase et al. 1995; Tschudi, & Luscher 1994). This balance of receptors may be
altered under pathophysiological conditions.
As a first step in understanding the contribution of the ETB receptor to the maintenance of vascular




Five healthy male subjects between 18 and 50 years of age were recruited to the study, which was
performed in the Clinical Research Centre at the Western General Hospital, Edinburgh with the
approval of the local research ethics committee and the written informed consent of each subject. The
investigations conformed to the principles outlined in the Declaration of Helsinki. No subject received
vaso-active medication or non-steroidal anti-inflammatory drugs in the week before each phase of a
study and all subjects abstained from alcohol for 24 hours and from food, caffeine containing drinks
and tobacco for at least 4 hours before any measurements were made. All studies were performed in a
quiet room kept at a controlled temperature between 22-24°C.
5.2.2 Drugs
BQ-788 (Clinalfa AG, Laufelfingen, Switzerland) was used as a selective ETB receptor antagonist, based
on a 1000 fold selectivity of BQ-788 for the ETB receptor, in the nanomolar range, in human cell lines
(Ishikawa et al. 1994) and on inhibition of ET-3 binding to recombinant human ETB receptors
expressed in Chinese Hamster ovary cells, also in the nanomolar range (Reynolds et al. 1995). The dose
range (3-300 nmol/min) used in the current study was selected from previous work investigating the
local effects of BQ-788 in the forearm circulation (Verhaar et al. 1998) and from a dose ranging pilot
study in which 2 volunteers were studied at each dose level (data not shown). Selected doses (1-300
nmol/min) were administered in the pilot study to identify a no effect dose and select an appropriate
maximum dose for the main study.
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BQ-788 was dissolved in physiological saline (0.9%; Baxter Healthcare, Ltd). Saline (0.9%; Baxter
Healthcare, Ltd) was administered as placebo. BQ-788 and placebo were administered single blind and
infused intravenously via an 18 SWG cannula sited in the left antecubital vein at a constant rate for 15
minutes. All solutions were prepared from sterile stock solutions on the day of the study.
5.2.3 Measurements
Plasma ET-1 and Big ET-1
Blood samples were obtained; pre-dose and at 5, 15, 60 and 240 minutes post dose, via an 18 SWG
cannula sited in the non-infused arm. In brief, 10 ml samples were collected into sterile EDTA tubes
(K3 EDTA, Vacutainer, Becton Dickinson Vacutainer Systems, Europe) centrifuged immediately at
2000 g for 20 min and stored in plain tubes at -80°C prior to assay. Plasma ET-1 and big ET-1
concentrations were measured as described in the methodology section (2.6.4).
Blood samples were also taken on admission and prior to discharge for safety tests (sodium, potassium,
creatinine, urea, alkaline phosphatase, gamma-glutamyl transpeptidase, hemoglobin and white cell
count).
Haemodynamic recordings
Haemodynamic recordings were made at 10 minute intervals from 30 minutes pre-dose until 1 hour
following the start of the infusion, with an additional blood pressure measurement at 15 minutes
corresponding with the end of the infusion, and then at 30 minute intervals until 2 hours and hourly
until 4 hours following the start of the infusion.
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BP and heart rate were recorded in duplicate and averaged for each time-point as described in the
methods section 2.2. BP is presented as mean arterial pressure (MAP; diastolic blood pressure + 1/3
pulse pressure, mm Hg).
CO and HR were recorded using bioimpedance technique as described in the methods section 2.3.
These parameters were corrected for body surface area and described as cardiac index (CI, 1/min/m2)
and stroke index (SI, ml/m2) [2], Total peripheral vascular resistance index (TPVRI) was calculated as
MAP divided by CI and expressed in arbitrary units (AU).
5.2.4 Study Design
The response to BQ-788 (3, 30 and 300 nmol/min) and placebo was investigated in a placebo
controlled, four way crossover study. Study drugs were administered single blind. The order of
treatments was randomised. Five subjects attended for 4 separate study visits, each separated by at least
5 days. Subjects were resident in the research centre for at least 6 hours. Subjects rested supine for at
least 20 minutes prior to haemodynamic measures and baseline measures were made in the 30 minutes
prior to study drug administration.
5.2.5 Data analysis and statistics
Plasma ET-1 and big ET-1 are represented as absolute change from pre-dose (pg/ml) with statistical
significance assessed by paired /-test. Haemodynamic results are expressed as maximum placebo
corrected percentage changes from baseline ± SEM [2], Statistical analysis was performed on
untransformed data. Responses were examined by repeated measures analysis of variance (ANOVA).
Statistical significance was taken at the 5% level and analysis was performed using an Excel data analysis
package (Excel 5.0; Microsoft Ltd, Wokingham, UK).
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5.3 Results
All five healthy male subjects (age range 33-48 years) completed the study. No adverse events were
reported and there were no clinically relevant changes in safety blood samples.
Plasma ET-1 and Big ET-1
There was no significant difference between pre—dose plasma ET-1 concentrations for any of the
treatments (range of baseline mean values 4.4-4.9 pg/ml). Plasma ET-1 concentration increased
significantly following administration of BQ-788 (from 4.6±0.8 to 8.4±1.8 pg/ml at 15 minutes with 300
nmol/min, p=0.02) but not during treatment with the lower doses of BQ-788 or placebo [Figure 1]. In
contrast, concentrations of big ET-1 did not change significantly with treatment.
Haemodjnamicparameters
Baseline measurements for haemodynamic parameters on the placebo treatment period were as follows:
MAP, 79±3 mmHg; HR, 79±3 bpm; CI, 2.6±0.2 1/min/m2; SI, 49±3 ml/m2; TPVRI, 31.1 ±1.8 AU.
Baseline values were similar for each of the other treatment periods. MAP did not alter significantly
following administration of BQ-788 at any dose (3±2% at 90 min with 300 nmol/min; p=0.4) [Figure
2]. Following administration of BQ-788, there were changes in all other haemodynamic parameters
when compared with placebo which appeared to be dose related and which were significant at 300
nmol/min; HR decreased (13±7% at 50 minutes post dose: p=0.002), CI decreased (17±5% at 40 min;
p<0.0001) and there was a small reduction in stroke index (8±4% at 40 min: p=0.002). TPVRI
increased (24±5% at 40 min; p<0.0001).
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5.4 Discussion
We have demonstrated substantial systemic vasoconstriction, associated with a reduction in HR and CI
but no change in BP, in response to administration of the selective ETB receptor antagonist BQ-788 in
healthy men. Consistent with our earlier work in the forearm circulation (Verhaar et al. 1998), these
observations are highly suggestive of the overall effect of endogenous ETB receptor mediated vascular
tone favouring vasodilatation. An alternative explanation for the haemodynamic effects is that BQ-788
is directly negatively chronotropic and that peripheral effects are indirect. Elowever, this is unlikely given
our earlier work (Verhaar et al. 1998) and the lack of evidence of an important positive chronotropic
and inotropic role of the cardiac ETB receptor (Zhu et al. 1997). Although peripheral resistance
(TPVRI = MAP / CI) was substantially increased, BP was unaffected because of a decrease in HR,
which was probably reflex in origin. It would be expected that this reflex bradycardia would be more
pronounced in younger, heallthy subjects. It is possible that if BQ-788 was administered to older or
hypertensive subjects a rise in blood pressure would be seen. Earlier work, as discussed above in
isolated vascular beds, such as the forearm (Verhaar et al. 1998), has demonstrated vasoconstriction
consistent with the rise in TPVRI that we observed. Taken in conjunction with other work on the role
of the cardiac ETB receptor (Zhu et al. 1997), which failed to demonstrate an inotropic effect with
stimulation of this receptor, out results are entirely consistent with a direct effect on peripheral
vasoconstriction. We have also demonstrated increases in plasma ET-1, but not big ET-1,
concentrations following ETB receptor blockade, consistent with reduced clearance of ET-1 by the ETB
receptor (Fukuroda et al. 1994). All of these effects were prominent with BQ-788 at the highest dose
but were not clearly seen at lower doses.
The vasoconstrictor effects of ETB receptor antagonism may result directly from blockade of the
vasodilator effects of the endothelial ETB receptor or indirectly from displacement of endogenously
generated ET-1 from ETB receptors to unoccupied ETA receptors. It is unlikely that these effects are
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mediated by non-selective ETA/B receptor blockade because they are the opposite of those found with
selective ETA receptor antagonists in healthy subjects (Spratt et al. 2001) and patients with heart failure
(Cowburn et al. 1998), and of those found with combined ETA/B receptor antagonists in healthy subjects
(Haynes et al. 1996). Clearly, the indirect effects of ET-1 on ETA receptors are more relevant with
administration of selective ETB antagonists than with non-selective ETA/B receptor antagonists, because
in this latter situation the constrictor ETA receptor is also blocked. Indeed, vasodilator effects have been
demonstrated with both selective (Haynes & Webb; Verhaar et al. 1998; Cowburn et al. 1998) and non¬
selective (Haynes et al. 1996; Kiowski et al. 1995) endothelin receptor antagonists in humans and the
non-selective ETA/B antagonist, bosentan, has recently been shown to effectively lower BP in patients
with hypertension (Krum et al. 1998). However, direct comparison of the effects of selective and non¬
selective endothelin receptor antagonism will be important in assessing the relative contribution of each
receptor subtype to the vascular effects of ET-1.
We and others have previously demonstrated forearm vasodilatation in response to local ETA receptor
antagonism with BQ-123 (Haynes & Webb; Verhaar et al. 1998; Berrazueta et al. 1997). In the presence
of BQ-788 in healthy volunteers this effect was attenuated (Verhaar et al. 1998), suggesting that the
overall effect of vascular ETB receptor stimulation by endogenous ET-1 is vasodilatation. This
attenuation of BQ-123 mediated vasodilatation by BQ-788 suggests that the vasoconstrictor effect of
ETb receptor blockade is not mediated by displacement of ET-1 onto the ETA receptor, but is due to
direct blockade of ETB mediated vasodilator tone. We have also shown, using a 'nitric oxide clamp'
technique, that the vasodilator response to BQ-123 is in part mediated by nitric oxide (Verhaar et al.
1998) and, therefore, probably mediated by the endothelial ETB receptor. Loss of endothelial cell ETB
mediated vasodilator tone may occur in cardiovascular diseases, such as essential hypertension and
hypercholesterolaemia, in which there is associated endothelial dysfunction (Casino et al. 1995; Panza et
al. 1995). Here, because of a reduced capacity for ETB receptor mediated, nitric oxide dependent
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dilatation, selective ETB receptor antagonists may be less effective. ETB mediated vasodilatation is also
in part mediated by generation of prostacyclin (de Nucci et al 1988), which is less likely to be affected by
changes in endothelial function, although the relative balance of vasodilatory effects are unclear.
In summary, we have demonstrated systemic vasoconstriction in response to acute ETB receptor
blockade with the selective ETB receptor antagonist BQ-788 in healthy men in vivo, indicating that the
predominant endogenous effect of stimulating vascular ETB receptors is vasodilatation. One exciting
possibility is that tonic endogenous ET-1 release, acting via the endothelial ETB receptor, is responsible
for the physiological basal release of nitric oxide. This now needs to be addressed in clinical studies.
Further investigation of the influence of ETB receptor antagonism on the sympathetic nervous system
and renal function are also warranted. In addition, direct comparison of the effects of chronic
administration of selective ETA and combined ETA/B receptor antagonists are required in patients with
cardiovascular disease, with and without endothelial dysfunction, in order to confirm which of these
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The change in plasma ET-1 concentrations (pg/ml) following a 15 minute intravenous infusion of BQ-
788 or saline placebo in five subjects: solid columns, BQ-788 (300 nmol/min); shaded columns, BQ-
788 (30 nmol/min); hatched columns, BQ-788 (3 nmol/min); open columns, placebo. Plasma ET-1
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Placebo corrected mean percentage change in hemodynamic parameters; mean arterial pressure (MAP),
heart rate (HR), cardiac index (CI), stroke index (SI), total peripheral vascular resistance (TPVRI)
following a 15 minute intravenous infusion of BQ-788 or saline placebo in five subjects: closed circles,
BQ-788 (300 nmol/min); open circles, BQ-788 (30 nmol/min); shaded diamonds, BQ-788 (3
nmol/min). There was no change in MAP, but there was a reduction in HR, CI and SI, and an increase
in TPVRI following administration of BQ-788 (300 nmol/min).
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6.2.6 Data analysis and statistics
6.3 Results
6.3.1 Haemodynamicparamenters









Angiotensin II (ANG II) is a powerful vasoconstrictor substance formed from angiotensin I (ANG I)
by the actions of the endothelial cell ecto-enzyme, angiotensin converting enzyme (ACE). The success
of ACE inhibitors in treating conditions such as hypertension and CHF underlines the importance of
ANG II in pathophysiological situations involving vasoconstriction (SOLVD investigators 1992;
SOLVD investigators 1991). ET-1 is one of the most potent vasoconstricting substances so far
discovered (Yanagisawa et al 1988). As with ANG II, the beneficial effects of endothelin receptor
antagonists (ERAs) in studies in animals and patients with cardiovascular disease suggest an important
role for ET-1 in such conditions (Goddard & Webb 1999). The overall effect of ET-1 on BP in man is
the result of a complex interplay between vasoconstriction mediated by vascular smooth muscle cell
endothelin subtype A (ETQ receptors and possibly vascular smooth muscle cell ETB receptors, and
vasodilatation and receptor-mediated clearance by endothelial cell ETB receptors (Haynes & Webb
1998; Strachan et al 1999; Spratt et al 2001).
Recendy, several lines of evidence have suggested that the effects of ANG II on vascular structure and
function are at least in part mediated by ET-1. Studies in rats have demonstrated that pre-treatment
with, or chronic administration of, ERAs can attenuate or even abolish the pressor response to chronic
ANG II infusion (Herizi et al 1998; d'Uscio et al 1997; Moreau et al 1997; Barton et al 1998; Ortiz et al.
2001; Alexander et al 2001). In contrast, acute administration of ERAs show no effect on (Gardiner et
al. 1999; Boemke et al. 2001) or, at best, only partial blunting of (Balakrishnan et al 1996; Heinemann et
al 1997; Riggleman et al 2001) the pressor response to acute ANG II infusions.
In this study, we have investigated the effects of acute ETA receptor blockade with the peptide BQ-123
(Ihara et al 1992) on the acute systemic haemodynamic effects of ANG II in man, using a dose of BQ-
123 known to have maximal haemodynamic actions and to block the vasoconstrictor effects of
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exogenous ET-1 (Spratt et al 2001). To allow for any non-specific hypotensive and vasodilatory effects




Eight healthy men (mean age 28 ± 4 years) were recruited to the study, which was performed in the
Clinical Research Centre at the Western General Hospital, Edinburgh. The study had the approval of
the local research ethics committee and the written informed consent of each subject. The
investigations conformed to the principles outlined in the Declaration of Helsinki. Subjects taking
prescription or over-the-counter medicines in the previous two weeks were excluded from the study. All
subjects were asked to abstain from alcohol, nicotine and caffeine-containing products for 24 hours,
and from food for at least 4 hours, before measurements were made. All studies were performed in a
quiet room kept at a controlled temperature between 22-24 °C with the subject supine throughout.
6.2.2 Drugs
BQ-123, a selective ETA receptor antagonist (Ihara et al 1992) (Clinalfa AG, Laufelfingen, Switzerland),
was infused at 1000 nmol/min for 15 min. This dose was selected from a previous systemic dose-
ranging study showing it to exert a maximal haemodynamic effect, abolish vasoconstriction to
exogenous ET-1 (Spratt et al 2001), not increase plasma ET-1, and have a peak plasma concentration
exceeding the K; for ETA receptor inhibition but twenty-fold lower than the IT for ET„ receptor
inhibition (Ihara et al 1992). ANG II (Clinalfa AG) was administered in ascending doses of 1, 3 and 6
ng/kg/min for 15 min at each dose. NE (Sanofi Winthrop, Guildford, UK) was administered in
ascending doses of 60, 120 and 210 ng/kg/min for 15 min at each dose as a control pressor agent. The
doses of ANG II (Collier et al 1973; Hollenberg et al 1976) and NE (Bramnert et al 1994) were chosen
from previously published studies to achieve a maximum increase in MAP of ~20 mmHg. Physiological
saline (0.9%, Baxter Healthcare Ltd, Thetford, UK) was administered as placebo. All drugs were
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prepared as described previously (Section 2.1.4), and infused intravenously at a constant rate of
lml/min via an 18 standard wire gauge (SWG) cannula sited in a left antecubital fossa vein.
6.2.3 Measurements
BP was recorded using a validated semi-automated non-invasive oscillometric device (section 2.2).
6.2.4 Plasma ET-1 andANG II
Ten ml of venous blood for the measurement of ET-1 was obtained from an 18 SWG cannula inserted
into a left forearm vein, before administration of BQ-123/placebo, at 30 min after BQ-123/placebo
infusion and after each dose increment of ANG II/NE. Samples were collected into sterile EDTA
tubes (K3 EDTA, Vacutainer, Becton Dickinson Vacutainer Systems, Europe). During the studies in
which ANG II was infused, an additional 10 ml blood for the measurement of ANG II was collected at
each time point and plasma ET-1 and ANG II concentrations determined as previously described
(Section 2.6.2).
6.2.5 Study design
This was a double-blind, placebo-controlled study. Subjects attended for a total of 4 studies. On two
study days they received ANG II, and on two NE. The subjects were randomly assigned to receive
ANG II or NE first and, for each pressor agent, subjects received BQ-123 or placebo in random order.
Each visit was separated by at least 3 days.
Subjects rested supine for 45 min on each occasion before beginning the study. BQ-123 or placebo
were then administered intravenously via the ante-cubital cannula at a constant rate for 15 min, followed
by saline for 15 min. ANG II or NE were then administered in incremental ascending doses. The timing
of the pressor infusions was chosen to correspond to the period of maximal vasodilatation of this dose
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of BQ-123 (Spratt et al 2001). Haemodynamic recordings were made in duplicate at 15 min intervals
from 45 min before administration of BQ-123 or placebo until completion of the ANG II or NE
infusions.
6.2.6 DataAnalysis & statistics
Data were stored and analysed using a statistical analysis package (Excel 5.0; Microsoft Ltd, Wokingham
UK). BP data at each time point were calculated as the mean of the two recordings.
Study baseline data were calculated as the mean of the two time points immediately preceding the
administration of BQ-123 or placebo. Because BQ-123 reduced BP, changes in MAP during pressor
infusions were calculated from the time point, immediately before the pressor infusions were started, 30
min after BQ-123 infusion commenced. Haemodynamic results are expressed as mean change from this
time point ± SEM. Responses were examined by repeated measures analysis of variance (ANOVA) and
Bonferroni correction was applied to examine significance identical time points. Statistical significance
was taken at the 5% level.
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6.3 Results
All 8 subjects completed the study. No adverse events were reported. Baseline haemodynamic
measurements were similar on all four study days (Table 1).
6.3.1 Haemodynamicparameters
After placebo, ANG II and NE both increased MAP in a dose-related manner. This rise in MAP at each
time point was similar for the two pressor agents (ANOVA P=0.13). Administration of BQ-123 was
associated with a small reduction in MAP at 30 min (Table 1) and a subsequent significant attenuation
of the observed pressor effect of both ANG II and NE (maximum attenuation, -6.3 ± 3.0 mmPIg,
ANOVA, P—0.02 vs. placebo for ANG II, -8.4 ± 4.0 mmPIg, P—0.05 vs. placebo for NE). This
attenuation was of a similar magnitude for both agents (P =0.22) (Figure 1).
6.3.2 Plasma ET-1 andANG II
In both ANG II and NE studies, plasma concentrations of ET-1 were not significantly different at any
time point. Plasma ANG II increased with each successive ANG II dose increment. There were no
significant differences in the plasma ANG II levels between the BQ-123 and placebo phases, although
there was a trend to higher levels in the BQ-123 phase (Table 3).
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6.4 Discussion
Our studies demonstrate that the effect of acute ETA antagonism on the pressor actions of ANG II in
man is modest and non-specific, having a similar effect on the pressor response to NE. This suggests
that ET-1, acting through the ETA receptor, does not account for the acute pressor effects of ANG II.
In rats, the evidence for such an interaction between the ANG II and ET systems in vivo has largely
rested on the results of chronic studies. Selective ETA and non-selective ETA/B receptor antagonists,
administered over 10 to 14 days to rats, have, however, produced varying results. Non-selective
antagonism with bosentan abolished the pressor effects of continually infused ANG II at 200
ng/kg/min (Herizi et al 1998) but not 400 ng/kg/min (Casellas et al 1997). Chronic ETA antagonism
with ABT-627 abolished the pressor effects of 50 ng/kg/min of ANG II (Alexander et al 2001) but the
ETa antagonist LU 135 252 only partially attenuated the pressor effects of ANG II at a dose of 200
ng/kg/min (d'Uscio et al 1997; Barton et al 1998). However, none of these studies included an ET
independent pressor agent as a control. In acute studies, by contrast, at best, only partial blunting of the
pressor response has been shown with both selective ETA (Riggleman et al 1998) and non-selective
ETa/b antagonists (Balakrishnan et al 1996; Heinemann et al 1997). Other acute studies with the non¬
selective antagonist SB209670 (Gardiner et al 1999) have failed to demonstrate a significant effect on
equivalent ANG II induced rises in BP. Similarly, in dogs, acute administration of LU135 252 has no
effects on the pressor response to 20 ng/kg/min ofANG II (Boemke et al 2001).
Because of evidence supporting the role of ETA receptors in the maintenance of vascular constrictor
tone (Haynes & Webb 1998; Spratt et al 2001), and, because non-selective ET receptor antagonists will
block nitric oxide and prostaglandin mediated vasodilatation via the ETB receptor, and thus,
theoretically reduce any effect on ANG II pressure response, we elected to use a selective ETA
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antagonist for this study. We have previously shown that our dose of 1000 nmol/min of BQ-123 for 15
min is at the top of the dose response curve in terms of the effects of BQ-123 on BP in healthy
volunteers, thus is likely to give maximal ETA receptor blockade (Spratt et al 2001). Pilot studies in the
department failed to demonstrate an effect of a lower dose 300 nmol/min of BQ-123 on ANG II
induced BP rise. However, in view of the above, it was felt this could equally be interpreted as
incomplete ET receptor blockade rather than the absence of an interaction between ANG II and ET.
Our chosen dose of BQ-123 has significant depressor actions in man (Spratt et al 2001). We, therefore,
elected to use NE as a control pressor agent to allow us to assess any non-specific hypotensive and
vasodilatory effects of BQ-123 at this dose. Previous animal studies have shown that ERAs, while
inhibiting ANG II induced contractions, had no effect on NE induced aortic ring contractions (Webb
et al 1992). Additionally, while ET and ANG II have been shown to be synergistic in elevating BP in
vivo, there is a lack of such synergism between ET and NE (Yoshida et al 1992). These data tend to
support our use of NE as an ET-independent pressor agent. As such, the similar efficacy of BQ-123 in
attenuating equivalent rises in BP induced by ANG II and NE leads us to conclude that the modest
effect of acute ETA blockade on the pressor actions of ANG II is non-specific. Additionally, although
the essentially paracrine nature of the ET system may makes interpretations of changes in plasma
concentrations difficult, the failure of ANG II or NE to change plasma ET-1 concentrations also
suggests that neither ANG II nor NE achieve their acute pressor effect by stimulating ET-1,
Our observation is consistent with the finding that both Selective ETA and non-selective ETA/B have an
added haemodynamic benefit in patients with CHF already treated with ACE inhibitors (Sutsch et al
1998) and supports the development of ERAs as adjunctive treatment in such patients. However, it
does not preclude an interaction between ANG II and ET-1 via ETB receptors. Nor does it preclude a
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chronic effect of ETA blockade on attenuating ANG II mediated cardiovascular remodelling or more
chronic adaptive changes.
In vitro evidence does suggest that ANG II can upregulate the ET system. ANG II can stimulate ET-1
gene transcription (Sung et al 1994; Imai et al 1992) and peptide secretion (Kohno et al 1992; Scott-
Burden et al 1991) in a variety of cell types, including endothelial and vascular smooth muscle cells,
probably via the AT-1 receptor (Ferri et al 1999). It is possible that we failed to detect an effect of
blocking this ANG II stimulated increase in ET-1 because such up-regulation, if occurring at the
transcription level, would not fully develop within the time course of this acute study. It remains
possible that such an interaction could exist chronically and that, in particular, some alterations to
vascular structure induced by ANG II may be mediated by ET-1.
In conclusion, we have found a moderate and non-specific effect of BQ-123 on the pressor response to
ANG II in man suggesting that ANG II does not achieve its acute pressor effect via ET-1. This
supports the development of ERA's as adjunctive treatments to ACE inhibitors of ET-1 receptor
antagonists.
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Mean arterial pressure at
baseline
(mmHg)
81.5 ± 2.5 83.5 ± 2.5 84.5 ± 2.8 83.1 ± 3.5
Mean arterial pressure at
30 min post BQ-123
(mmHg)
81.5±2.2 81.1 ±2.7 82.7±3.1 81.3±2.7
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Table 2: Plasma ET-1 concentrations (pg/ml) (mean ± SEM).
ANG II ANG II NE NE
+ Placebo + BQ-123 + Placebo + BQ-123
Baseline 2.41 ± 0.35 3.81 ± 0.51 2.72 ± 0.41 2.32 ± 0.23
30 min post BQ-123 3.07 ± 0.12 3.05 ± 0.28 2.67 ± 0.55 2.40 ± 0.44
Post ANG II (1 2.74 ± 0.42 3.47 ± 0.49 2.88 ± 0.38 3.06 ± 0.28
ng/Kg/min)/ NE (60
ng/Kg/min)
Post ANG II (3 3.10 ± 0.27 3.21 ± 0.33 3.38 ± 0.68 3.13 ± 0.43
ng/Kg/min)/ NE (120
ng/Kg/min)










30 min post BQ-123 23.4±8.6 11.8±2.2
Post ANG II (1 ng/Kg/min)/ NE
(60 ng/Kg/min)
34.7±4.5 27.2±4.7
Post ANG II (3 ng/Kg/min)/ NE
(120 ng/Kg/min)
67.8±8.5 83.2±20.4











MAP during ANG II and NE infusions following placebo (□) or BQ-123 (♦). Data are expressed as
mean change from baseline + SEM. *P<0.05 placebo vs. BQ-123 (ANOVA + Bonferroni correction).
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Study 5: The systemic haemodynamic effects of selective ETA blockade
versus non-selective ETA/ETB blockade in patients with chronic heart








7.2.6 Data analysis and statistics
7.3 Results
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7.3.1 Cardiac output and heart rate
7.3.2 Left ventricularfillingpressure and systemic haemodynamics
7.3.3 Right ventricularfillingpressure andpulmonary haemodynamics








Endothelin-1 (ET-1) is the most potent endogenous vasoconstrictor in man and acts via two
receptors; the ETA and ETB. Both receptor subtypes are expressed on vascular smooth
muscle cells where they mediated vasoconstriction whilst only the ETB receptor is located on
the endothelium producing a prostanoid and nitric oxide mediated vasodilatation. Therefore
the ETa receptor mediates vasoconstriction whilst the actions mediated via the ETB receptor
are more complex, and include vasodilatation, vasoconstriction and a role in the clearance of
plasma ET-1.
The ET system contributes to the maintenance of basal vascular tone and blood pressure
and blockade of the ETA receptor causing vasodilatation and vasodepressor effects while
ETb receptor blockade has vasoconstrictor and pressor actions. Thus the balance of effects
at the ETB receptor appears to be in favour of vasodilatation.
The renin-angiotensin and sympathetic nervous systems in part mediate neurohumoral
reflexes that lead to peripheral vasoconstriction and increased systemic vascular resistance.
However, the ET system also contributes to the pathophysiology with increased plasma ET-
1 and big ET-1 concentrations (Hiroe et al 1991, McMurray et al 1992, Cody et al 1992, Wei et
al 1994) that correlate with a poor prognosis (Pousset et al 1997). The use of drugs to block
the renin-angiotensin and sympathetic nervous systems and cause a reduction in systemic
vascular resistance have been demonstrated to improve outcome in patients with CHF. The
potentially detrimental haemodynamic effects of ET-1 and the finding of elevated plasma
concentrations suggest that the ET system may provide a therapeutic target in CHF.
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Short-term systemic selective ETA blockade in stable patients with CHF reduces systemic
vascular resistance and increases cardiac output (Cowburn et al 1998, Givertz et al 2000,
Spieker et al 2000, Ruschitzka et al 2001). In addition, dual ETA/B blockade reduces systemic
vascular resistance and increases cardiac output in patients with CHF (Kiowski et al 1995,
Packer et al 1998, Sutsch et al 1998, Schalcher et al 2000, Torre-Amione et al 2001, Abraham et
al 2001). Flowever, short-term systemic selective ETB blockade increases SVR suggesting
that the balance of action at the ETB receptor is in favour of systemic vasodilatation in
patients with CHF (Cowburn et al 1999).
To date there have been no direct head-to-head comparisons between selective ETA
blockade and dual ETA/B blockade. The aims of this study were to determine, in patients
with stable CHF, the effects of selective ETA blockade compared with dual ETA/B blockade
on systemic and pulmonary haemodynamics and to study the effects on plasma




Nine patients with CHF (New York Heart Association Grade II — III) due to left ventricular
dysfunction were recruited if they had an ejection fraction of less than 35% (by
echocardiography Simpson's rule) and had been stable on therapy, including angiotensin
converting enzyme inhibitors or angiotensin receptor antagonists, for at least 3 months.
Patients were excluded if they had insulin dependent diabetes mellitus, abnormal liver
function tests, recent myocardial infarction, coronary artery bypass grafting or coronary
artery intervention in the previous 3 months, renal impairment (creatinine >200 pmol/L for
men; >180 pmol/L for women) or had a systolic BP >190 or <90 mmllg.
The study was undertaken with the approval of the local research ethics committee and in
accordance with the Declaration of Helsinki. Written informed consent was obtained from
each subject before entry into the study.
7.2.2 Drugs
A venous cannula (Venflon®; Ohmeda, BOC Ohmeda AB, Helsingborg, Sweden) for drug
adminstration was inserted under local anaesthesia (EmlaIM cream 5%; Astra
Pharmaceuticals Ltd, Kings Langley, UK). Pharmaceutical grade BQ123 and BQ788
(Clinalfa AG, Laufelfingen, Switzerland) were dissolved in 0.9% saline (Baxter Healthcare
Ltd, Thetford, UK). Patients received on different study days and in random order saline
placebo, BQ123 (100 and 1000 nmol/min) or BQ123 (100 and 1000 nmol/min) and
concomitant BQ788 (30 and 300 nmol/min). On all study days patients received low dose
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infusion at t = 0 for 15 min followed by high dose infusion at t = 60 min for 15 min.
Because of safety issues the principle investigator was not blinded but other investigators
were to the treatments given.
7.2.3 Measurements
BP was recorded using a validated semi-automated non-invasive oscillometric device (section
2.2). CO, mean pulmonary artery pressure (PAP), pulmonary capillary wedge pressure
(PCWP) and CVP were measured via a thermodilution cardiac output pulmonary artery
catheter (section 2.5).
7.2.4 Drug assays
Venous blood for routine biochemistry and hormone assay was taken from the femoral vein.
Plasma was assayed for ET-1 and big ET-1 (section 2.6).
7.2.5 Study Design
All patients attended fasted at 7.30 am on 3 occasions 1 week apart. Haemodynamic
measurements were made in a quiet, draught free room maintained at a constant temperature
(22 - 24 °C). After catheter insertion, patients underwent an equilibration period of at least
90 min until BP, HR and CO were stable with 3 consecutive measurements within 10%
before commencing the study. Study drugs were administered by 15 min infusion in 2
incremental doses 60 min apart. The parameters were recorded in a double blind manner
although for safety reason the principle physician present was un-blinded.
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7.2.6 Data analysis and statistics
Data are expressed as mean percentage change from baseline +/- SEM unless otherwise
specified. Mean area under the curve +/- SEM for responses was calculated. Data were
examined by repeated measures ANOVA and Student's t-test with Bonferroni correction
(Excel v5.0, Microsoft). Statistical significance was taken at the 5% level.
7.3 Results
Patients' characteristics and medication are shown in Table 1. There were no significant
adverse events and the study was well tolerated by all patients. There were no significant
differences in baseline haemodynamic variables between study visits.
7.3.1 Cardiac output and heart rate
BQ123 infusion caused an increase in CO (p = 0.03 vs placebo) with a maximum increase of
33% at 75min. Combined BQ123 and BQ788 infusion significantly attenuated these effects
(p < 0.05 vs BQ123) (Figure 2). There was a small increase in FIR with both BQ123 and
combined BQ123 and BQ788 infusion of ~10% (ANOVA, p = 0.002 and 0.007 respectively
vs placebo; Figure 1).
7.3.2 Deft ventricularfillingpressure and systemic haemodynamics
Both BQ123 and combined BQ123 and BQ788 infusion reduced PCWP by ~ 20% (p =
0.016 and 0.0004 respectively; Figure 2). MAP was reduced by BQ123 (p = 0.001 vs placebo)
with a maximal decrease of 13% at 150 min. Combined BQ123 and BQ788 also significantly
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reduced BP (p = 0.008 vs placebo) and this was not significandy different from BQ123 alone
(p = 0.2) (Figure 1). SVR was therefore significantly lowered by BQ123 compared with
placebo (p = 0.01) and compared with combined BQ123 and BQ788 (p = 0.04) (Figure 3).
7.3.3 Right ventricularfillingpressure andpulmonary haemodynamics
Although there was a small statistically significant rise in CVP with concomitant BQ123 and
BQ788, this was not a consistent finding (Figure 3). Mean PAP was significantly reduced by
both BQ123 and combined BQ123 and BQ788 compared with placebo by a maximum of
25% at 90 min (p = 0.01 and 0.005 respectively) (Figure 4). Both treatments resulted in a
reduction in PVR (p = 0.006 and 0.005) but because of differential effects on CO selective
ETa blockade with BQ123 resulted in a larger reduction in PVR (p = 0.02 vs BQ123 +
BQ788) (Figure 4).
7.3.4 Plasma ET-1 and big ET-1
There was no significant increase in plasma concentrations of big ET-1 with placebo, BQ123
or combined BQ123 and BQ788 infusion. There was no significant increase in plasma
concentrations of ET-1 with placebo or BQ123, however, combined BQ123 and BQ788
caused a dose dependent increase in plasma ET-1 concentrations after both low dose (39 ±
14%, p = 0.02) and high dose antagonism (75 ± 24%, p < 0.02) (Figure 5).
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7.4 Discussion
We have shown for the first time, in a randomised placebo controlled trial, that there are
differences between selective ETA blockade compared with dual blockade in patients with
CHF. In our study selective ETA blockade and dual blockade reduced SVR, pulmonary
vascular resistance and increase in CO, however there were potentially important differences
between these two treatment strategies. In our study, dual ETA/B blockade resulted in
significant a reduction in PAP, but although there was a trend towards a greater effect than
with selective ETA receptor blockade it failed to reach significance.
There is increasing evidence that the ETB has a role in the clearance of plasma ET-1 with
increases in plasma ET-1 following systemic ETB blockade in both healthy volunteers
(Haynes et al 1996, Plumpton et al 1996, Strachan et al 1999, Goddard et al 2001) and patients
with CHF (Weber et al 1996, Kioski et al 1995, Sutsch et al 1998, Krum et al 1998). However
the effects of systemic ETA blockade are less consistent with little net increase, if any, in
plasma concentrations of ET-1 in either group (Verharr et al 1998 Spieker et al 2000, Givertz
et al 2000, Cowburn et al 1998). These results are confirmed in our study as selective ETA
blockade did not increase plasma ET-1 concentration whereas concomitant ETB blockade
increased plasma ET-1 after both low dose (39 ± 14%, p = 0.02) and high dose antagonism
(75 ± 24%, p < 0.02). Thus, selective ETA blockade has the benefit of leaving the ETB
receptor, with its ET-1 clearance role, unblocked and does not increase plasma ET-1. This
will avoid not only the adverse effects of raised ET-1 concentrations on systemic
haemodynamics primarily mediated through the ETA receptor, but also the non-
haemodynamic adverse effects of ET-1 such as mitogenesis etc.
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However there may be situations where blockade of the ETB receptor is desirable. There is a
higher density of ETB receptors in the pulmonary vasculature and there is evidence
suggesting that these are up-regulated in patients with pulmonary hypertension. Raised PAP
is an independent risk factor in patients with CHF and responses poorly to conventional
therapies. Dual ETA/B blockade may be of more benefit in patients with raised PAP. Indeed,
Bosentan, a dual ETA/B antagonist, has recently received a licence for the treatment of
primary pulmonary hypertension in the USA (Rubin et al 2002). The effects in patients with
pulmonary hypertension secondary to CHF are not known.
Our results are in general agreement with results from other, single drug studies, however,
the literature is somewhat complicated by the often arbitrary distinction between selective
and dual receptor blockers. There is considerable variation between the available ET
receptor blockers in term of receptor specificity and binding affinity for the two receptor
subtypes and indeed this may differ between tissues, in vivo.
The use of accurate invasive monitoring techniques such as pulmonary artery catheterisation
limits the duration of each study visit safety reasons and thus only the short-term effects of
these treatments could be assessed. Although a longer run in period would have been
preferable we addressed this issue by inclusion of a placebo limb. Indeed there were small
changes in the placebo. This is a short-term haemodynamic study and whether the
potentially beneficial haemodynamic changes confer benefit in terms of morbidity and
mortality will require large scale trials.
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While our study suggests that selective ETA blockade may provide greater, systemic
haemodynamic changes over dual ETA/B blockade the effects were less clear in the




Baseline characteristics of study subjects, including age, smoking history, ejection fraction,




This illustrates changes in HR & MAP with time, demonstrated graphically on the left for
placebo infusion; BQ-123= ; BQ-788 = . The bar charts on the right of the figure
demonstrate compartitive changes with placebo, BQ-123 and BQ-788.
Figure 7.2
This illustrates changes in CO and PAW with time, demonstrated graphically on the left;
BQ-123= , BQ-788» = . The bar charts on the right of the figure demonstrate comparititive
changes with placebo, BQ-123 and BQ-788.
Figure 7.3
This illustrates changes in SVRI & CVP with time, demonstrated graphically on the left; BQ- o
123 =, *BQ-788= . The bar charts on the right of the figure demonstrate comparititive
changes with placebo, BQ-123 and BQ-788.
Figure 7.4
This illustrates changes in PVR & MPAP with time, demonstrated graphically on the left; o
BQ-123=«; BQ-788= . The bar charts on the right of the figure demonstrate comparititive
changes with placebo, BQ-123 and BQ-788.
Figure 7.5
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This illustrates changes in big ET and ET-1 with time for each individual subject, for




Sex Age BMI EF% Smoker? BP P Coronaries NYHA
1 M 75 26 35 N 186/79 52 CABG'87 III
2 M 63 23 35 N 120/74 64 Normal II
3 M 60 27 35 N 122/58 62 MI'78 III
4 M 60 23 34 N 120/84 93 MI'87 II
5 M 43 30 20 N 98/64 77 MI'82 II
6 F 61 21 23 N 92/62 88 3 VES III
7 M 56 29 35 N 139/88 96 MI'95 III
8 M 61 26 30 N 136/77 66 MI'99 III
9 M 52 36 25 N 184/106 94 CABG'93 III
10 M 74 33 35 N 143/75 58 CADxl III
11 M 67 21 35 N 154/78 65 CADx3 II
AVE 61 27 31 136/77 74
SEM 3 1 2 9/4 5
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8.1 General comments and background
This MD thesis originally began as an extension of a colleague's work started in 1996 and the
latest paper from the work presented therein is expected to be published in 2003. This
timespan goes a long way to explain the diversity of work contained within. This work
focuses on the mechanism behind the role of endothelin on the cardiovascular system, a
system that was being rapidly explored in a search for medications to favourably impact on
cardiovascular disease.
8.2 Comments re mechanistic studies
There is a general similarity in the ways that these studies were carried out, which carries
both strengths and weaknesses; although these largely relate to the way they are interpreted.
Without exception these are mechanistic studies which use receptor antagonists to unmask
the role of the agent being studied either in a physiological or a pathophysiological situation.
As mechanistic studies they have been designed to explain mechanisms and degrees of
actions of the agents investigated, thus providing a basis for further directed drug
development. As alluded to, mechanistic studies are generally carried out in small subject
groups with the results designed to be interpretated on this basis. Important information can
be obtained about interactions between compounds and with local studies direct actions on
isolated arterial beds.
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8.3 Comments reforearm bloodflow studies- study 1; study 2
Whilst the results from local arterial studies can be extrapolated to give information on
systemic haemodynamics, they should be regarded primarily as an impetus for further
discussion. The strengths of forearm studies are also, in some cases, their weakness. Due to
isolation of the studied arterial bed, in this case the forearm, the effects of the study drug on
vasoreactivity can be determined. This isolation has several advantages: much lower doses of
drugs can be used, greatly reducing or eliminating the possiblity of systemic side-effects —
which can be particularly important in newly discovered drugs with a relatively unknown
side-effect profile; no activation of baroreceptors occurs, which is particularly evident in
young healthy subjects and may obscure the true effects of the study medication; as the
other forearm acts as a contemparaneous control even relatively small numbers of subjects
can give accurate, reproducible results, indeed the same subject can return on several
occasions for dose-ranging studies due to the short-lived nature of the studies. This is
particularly relevant in study 1, where with relatively small subject numbers we demonstrated
vasoconstriction in the forearm with the NEP inhibitorss candoxtrilat and thiorphan, results
later confirmed by systemic studies showing that oral doses of candoxatril in healthy men
produced an increase in both systolic blood pressure and venous plasma endothelin
concentration (Ando et. al. 1995; Motwani et. al. 1995). Yet on the other hand forearm
studies are by defination acute studies, which examine only the vascular effects of a short-
term infusion of the study medication; it is also assumed that the forearm vascular bed will
provide an accurate reflection of the effects of the study medication on the other vascular
beds in the body — although this is generally an accurate assumption.
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In study 1, the conclusion reached, that NEP inhibitors produced systemic vasoconstriction,
due to the balance of their effects on vasoconstrictors such as endothelin and vasodilators
such as bradykinin helped to explain why, despite causing significant naturesis NEP
inhibitors failed to lower blood pressure. In retrospect this study has proved influential in
influencing the development of some of the newer anti-cardiac failure treatment, such as
omapatrilat.
8.4 Comments re short-term systemic antagonist studies — studies 2,3,4 & 5
In all the studies intravenous agents are used, therefore limiting these studies to short
duration in resting subjects. This limits the conclusions that can be drawn, as it does not
allow for the effects of tolerance to develop or indeed changes in receptor actions or density.
Furthermore it provides "snapshot" information of the effects of the studied medication,
which does not allow for changes in physiological state.
All of the studies (2-5) in which we used short-term administration of agents to examine
their haemodynamic effects have similar limitations: the patient numbers were low — these
were calculated beforehand based on the expected haemodynamic changes, for safety
reasons as well as financial it was felt necessary to perform these studies with the minimum
number of subjects. In retrospect, with particular relevance to study 5, this limited the
conclusion that we were able to draw and in some circumstances we failed to reach
significance due to insufficient numbers. I feel that these compromises are inevitable with
grant-driven research which aims to get the maximum "bang per buck"! Furthermore with
respect to studies 2 to 4 one of the major limitations was the method of measuring the
haemodynamic changes — cardiac bioimpedance, which is in essence a derived measure
subject to a number of assumptions. This compromise was made as we were working with
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non-patient groups, i.e. healthy subjects recruited and paid according to study length. It was
felt that the additional risk of invasive monitoring with Swan-Ganz catheterisation and radial
artery blood pressure monitoring could not be justified, there is no doubt it would have
considerably added to the expense as well. In retrospect I feel that this was probably not a
justified concern and although the integrity of the studies were not significantly
compromised, more inclusive monitoring may have helped particularly with systemic
infusion of BQ-788. In this study it was particularly difficult to tease out the relative effects
of the study medication, where we observed an increase in TPVRI along with a decrease in
CI and HR. It was necessary to draw conclusions from several studies - those examining the
effects of ETb receptor stimulation on isolated cardiac tissue as well as forearm studies
showing vasoconstriction with BQ-788. With appropriate invasive monitoring, including
right heart pressures we could have clearly delineated these effects. The same comments also
apply to study 4. Yet both our systemic studies, infusing BQ123 and BQ-788 were the first
in man to demonstrate significant Haemodynamic changes and as such have formed an
important basis for future work.
8.5 Conclusions &future directions
In general I believe that the studies contained within this thesis were well constructed and
answered the questions they were designed for, within the confines of the limitations
described above. In particular they have helped to answer important questions about the
role of the ETA & ETB receptors in both health and disease. Although a large scale
randomised study investigating the effects of the mixed ETA / ETB receptor antagonist,
bosentan, have failed to demonstrate benefit in congestive heart failure (Kalra et al. 2002),
bosentan is now licensed for the treatment of primary pulmonary hypertension (Rubin et al
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2002) proving that endothelin antagonists still have a future in the management of
cardiovascular conditions. Indeed our study in CHF, conceived prior to either of the
previous 2 studies, suggested 2 things which may yet prove to be prophetic:: firstly that
selective ETA receptor antagonism offers additional haemodynamic benefit over mixed ETA
/ ETb receptor antagonism in CHF and secondly that the haemodynamic benefit of selective
ETa receptor antagonism may not extend to the pulmonary circulation. It may be that the
future of research in this area lies in this direction, finding the balance between selective and
mixed receptor antagonism in pulmonary hypertension and CHF. Other areas which may
prove of promise are the development of mixed antagonists (angiotensin / endothelin) to
treat remodelling following myocardial infarction or aggressive myocardial hypertrophy
secondary to hypertensive heart disease or the aggressive smooth muscle, almost tumour-like
growth seen following angioplasty-induced injury which manifests as restenosis.
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